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ABSTRACT 
The Influenza virus is responsible for hundreds of thousands of deaths and millions of 
infections worldwide each year. In spite of the annual seasonal influenza vaccine and various 
therapeutics that currently exist, influenza currently poses a major health hazard to the world’s 
population. Vaccine efficacy is diminished due to the high mutation rate commonly exhibited by 
negative sense RNA viruses. This complicates the decision for which strains to include in the 
yearly vaccine, and often results in poorly matched vaccine and circulating strains. Antivirals are 
available to combat influenza infection, but are also becoming less effective due to the increasing 
development of antiviral resistance and the limited selection. The development of improved 
vaccine strategies and novel antivirals are of critical importance to the public’s health and 
wellbeing. 
Our research group has collaborated with researchers at the University of Washington in 
the evaluation of computationally designed influenza antiviral binder proteins.  These proteins 
bind to the viral hemagglutinin surface protein and mimic antibodies that are naturally elicited in 
vivo during influenza infection, and prevent virus from binding and infecting cells by inhibiting 
the conformational change necessary for viral entry to host cells. Prior work evaluated viral 
protein binder HB36.6, demonstrating its efficacy against pandemic H1N1 in the ferret model.  
The present thesis was designed to evaluate an improved, smaller mini-binder that is less toxic 
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 v 
and more soluble in the ferret model.  Studies were designed to compare intranasal and 
intratracheal administration of mini-binder A13r33 administered 24 hours prior to aerosol 
challenge with pandemic H1N1 in ferrets. Our working hypothesis was that the antiviral 
minibinder A13r33 would result in reduced infection as measured by improved clinical outcome 
and lower viral loads following virus challenge. Ferrets were monitored for 7 days post infection 
for clinical, viral and immunological parameters. Results from these studies are presented in this 
thesis and provide compelling data for further evaluation of broadly protective novel therapeutics 
against influenza viruses. 
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1.0  INTRODUCTION 
1.1 THE INFLUENZA VIRUS 
1.1.1 Virus Structure and History 
Influenza has likely afflicted mankind since early humans began domesticating animals. 
Historical documents from fifth century B.C.E. Greece, the Middle Ages, and the European 
Renaissance report of epidemics that shared symptoms with influenza (1). Though it is difficult 
to know with absolute certainty that influenza was the direct cause in all these cases, there 
remains strong evidence that this virus has plagued humanity since before its confirmed debut in 
1899 with the Russian/ Asian Pandemic. The most famous influenza pandemic, the 1918 Spanish 
Flu was one of the worst disease outbreaks in human history, and is thought to have been 
responsible for somewhere around 500 million infections and between 50 and 100 million deaths 
(2). Since then numerous influenza pandemics, epidemics, and epizootic episodes have occurred. 
While none of these events have led to such widespread infection and death nonetheless 
influenza remains a dangerous infectious agent that continues to plague mankind.  
Influenza is a negative-sense, single-stranded RNA virus of the Orthomyxoviridae family.  
There are three viral subspecies comprised of A, B, and C. Of the three subspecies only A and B 
are known to cause infection in humans.  Regardless of subspecies all viruses possess eight 
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genetic segments encoding 11 or 12 known proteins. These genetic segments are packed together 
with a nucleocapsid protein, and together these protein-RNA complexes are packed into a capsid 
enclosed by a lipoprotein membrane. Influenza A viruses are further subdivided and classified by 
their glycoproteins hemagglutinin (HA) and neuraminidase (NA), which are present on the viral 
envelope. There are 18 known hemagglutinin and 11 neuraminidase glycoproteins specific to 
influenza A, however only three HA and two NA subtypes have been responsible for human 
pandemics (3). Hemagglutinin is important for viral attachment to sialic acid residues found on 
the surface of target cells, allowing the virus entry into those cells (4, 5). Neuraminidase is an 
exosialidase, cleaving sialic acid residues on the cell surface. This allows newly budded daughter 
virions from reattaching to the surface of the cell they emerge from, preventing aggregation and 
increasing the infectivity of the virus (6).  
 3 
 
Figure 1. The Influenza Virion. 
Three dimensional representation of the surface of an Influenza virion. 1. Hemagglutinin molecule. 2. 
Neuraminidase molecule, 3. M2 Protein channel. (CDC: https://www.cdc.gov/flu/images.htm).  
 
The influenza virions specifically target the epithelial cells that line the upper and lower 
respiratory tract. As has been mentioned prior hemagglutinin molecules on the surface of the 
virus bind directly to sialic acid residues which is critical for viral entry (4, 5). Sialic acid 
residues are a diverse family of sugars. They are composed of a nine-carbon backbone and are 
ubiquitously distributed on the terminal ends of glycoproteins which coat cellular surfaces. 
Influenza hemagglutinin molecules display a preference for the sialic acid residues they bind. 
Avian strains bind to α-2, 3 linked sialic acids which are found intestinal epithelium of birds, 
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while human specific strains bind more to α-2, 6 linked sialic acids, which are found in 
respiratory epithelium (7). Following attachment the viral particle triggers endocytosis, via its 
hemagglutinin molecule, allowing for viral entry into the endosome. As the pH of the endosome 
drops a conformational change allows hemagglutinin to insert the fusion peptide into the 
endosome membrane and form a pore. The virus then releases its genome segments through this 
pore into the cell (8). Viral ribonucleoprotein must then travel to the nucleus in order for 
replication to occur. The NP, PA, PB1, and PB2 proteins which comprise the protein elements of 
influenza ribonucleoprotein contain nuclear localization signals, allowing this complex entry into 
the host cell nucleus. As the genome segments are negative sense RNA, the first step in viral 
replication requires positive sense RNA production. This allows for both the translation of viral 
protein as well as serves as a template for negative sense RNA. Viral RNA dependent RNA 
polymerase (comprised of PB1, PB2 and PA) generates viral messenger RNAs (mRNAs) (9). 
These mRNA possess a 5’ methylated cap and a 3’ poly A tail. The poly A tail is found in the 
viral ribonucleoprotein but the methylated cap is stolen by a process called “cap snatching.” This 
involves the RNA dependent RNA polymerase’s binding to the methylated cap of host mRNAs 
and cleaving it from the cellular mRNAs. This cap is then used to prime the nascent viral mRNA 
(10). This prevents viral RNA from being degraded prior to translation as well as interferes with 
the production of cellular proteins, limiting competition between host and viral protein 
production. Assembly of the protein and nucleoprotein elements then occurs, taking place at lipid 
rafts found on the inner wall of the cell membrane. These lipid rafts are sections of membrane 
that are cholesterol and sphingolipid enriched. Following assembly completion budding occurs. 
This results in a new daughter virion encased in a section of host membrane with the 
hemagglutinin and neuraminidase molecules functional domains extruding (11).    
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Figure 2. Influenza Virus Life Cycle. 
 
1.1.2 Virus Epidemiology 
Seasonal influenza strains are responsible for wide spread economic loss, morbidity, and 
death worldwide. In 2003 influenza was responsible for causing and around 22,000 to 25,000 
deaths as well as estimated cost of over $87 billion in the United States alone (12, 13). Seasonal 
influenza can adversely affect a large portion of the entire population and is easily transmitted 
via coughing, sneezing, and droplets. Many of the infected will suffer from “flu like symptoms” 
such as fatigue, fever, muscle and joint pain, and sore/ running nose and throat. However 
children, the elderly, and the immune compromised are at risk of suffering from increased 
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disease severity (WHO Influenza Seasonal, 
http://www.who.int/mediacentre/factsheets/fs211/en/). 
1.1.3 Influenza Pandemics  
Influenza pandemics may have caused more deaths than died in both World Wars, 
combined. However it has been difficult without the advent of technologies like reverse 
transcription polymerase chain reaction (RT-PCR) to identify with certainty the pandemics for 
which influenza has been responsible. Other methods such as “seroarchaeology”, which analyzes 
antibodies taken from the elderly who lived through earlier pandemics, has also helped to 
identify pandemics caused by influenza (14). The earliest identified influenza pandemic occurred 
between 1899-1890, likely originating in Russia or Northern Asia and spread throughout Asia, 
Europe, and North America. Seroarchaeology concluded that this pandemic was likely caused by 
an H3 strain, which did not re-emerge as a pandemic strain until 70 years later as the 1968 Hong 
Kong Flu strain (14).  
The next identifiable influenza pandemic is the 1918 H1N1 Spanish Flu epidemic which 
spread worldwide. It is likely that the virus adapted over several months or years into the highly 
pathogenic and infectious strain that killed an estimated 3 to 6% of the world’s population. 
Reports of smaller localized outbreaks prior to the 1918 debut are likely attribute to earlier, less 
lethal strains. It is unknown exactly where the strain originated, though some evidence suggests 
it either originated in China and was brought to the United States before spreading worldwide or 
originated in the US (2).  
The Spanish Flu’s etymology arose from the wartime practice of censoring the news. 
Only Spain, which was neutral reported freely on the epidemic within their country, thus leading 
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to the pandemic’s name (1). Following this outbreak influenza remained as a seasonal cause of 
localized epidemics, the next pandemic did not occur until 1957 with the H2N2 Asian Flu.  
The H2N2 Asian Flu strain caught the world off guard as its hemagglutinin subtype was 
unlike that of previously identified human infectious strains (15). The 1918 strain primarily 
caused death by secondary or concomitant bacterial infections of the lungs which caused edema 
and lung consolidation, according to the American CDC and NIH (15) 
(https://www.nih.gov/news-events/news-releases/bacterial-pneumonia-caused-most-deaths-1918-
influenza-pandemic). Most of those killed by the 1918 strain were previously healthy, from age 
groups usually that are less hard hit by the virus. Many who died from the 1957 strain however 
already suffered from chronic cardiac and/ or lung diseases. However deaths of individuals with 
no known health complications also occurred, and women in the later stages of pregnancy were 
known to vulnerable to the virus as well (16).   
The next major influenza pandemic occurred in 1968 with the H3N2 Hong Kong flu 
outbreak. The outbreak occurred from 1968 to 1970, divided into two flu seasons. The United 
States and Canada suffered the most deaths in the 1968/1969 season, likely because there was 
reduced immunity to the neuraminidase subtype these populations. It is believed that the rest of 
the world had likely been immunized by the previous 1957 pandemic. Most of the deaths that 
occurred the 1969/1970 season occurred outside of North America, likely caused by antigenic 
drift of the neuraminidase (17).  
In 1977 H1N1 returned as a pandemic strain, nearly 70 years after the deadly 1918 
pandemic. Between 1918 and 1957 the H1N1 strain had remained as a seasonal strain causing 
local epidemics, which also immunized the survivors against this strain of influenza (1). 
However after 1957 this strain was supplanted by the H2 and H3 strains, and so primarily 
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children and young adults who had not been exposed to the H1 strains were the most susceptible. 
It is believed that the 1977 Russian strain pandemic did not naturally occur, but was either 
caused by an accidental release from a research lab or was kept frozen in the Russian permafrost 
or artic waters before being released (1, 18) 
Most recently in 2009 H1N1 re-emerged again as a pandemic strain, however most of the 
world had prepared for the next outbreak of avian H5N1 and had prepared their response 
accordingly (CDC H1N1 Flu: https://www.cdc.gov/h1n1flu/cdcresponse.htm). By the time the 
WHO had declared the pandemic over in 2010 here had been 18,500 laboratory confirmed 
deaths, however models predicted that it was more likely that 150,000 to 575,000 had actually 
died as a direct cause of infection (19).   
The 2009 pandemic flu, first isolated from humans in California and Mexico, was a 
reassortment of at least three different influenza virus parental strains. Six of this influenza 
strain’s genes share sequence homology with H1N2 strains first isolated from swine in 1999 and 
2000. The other two genes are from different Eurasian avian-like viruses. Its neuraminidase gene 
is closest to that of an H1N1 viruses isolated in Europe, while the matrix protein gene is similar 
to an H3N2 strain first isolated in Asia. Currently the exact sequence of events that led up to the 
creation of the pandemic 2009 strain are unknown. One hypothesis is that migrating birds and 
pigs that were a part of the international live swine trade intermingled, allowing these various 
viruses to reassort (20).  
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Figure 3. Timeline of Pandemic Strains of Influenza from 1899 to Modern Day. 
1.2 INFLUENZA PREVENTION AND TREATMENT 
Currently vaccination is considered by the CDC and WHO as the best method of 
preventing influenza infection as well as controlling the spread of the virus through the 
population. Unfortunately many individuals forgo vaccination which puts both them and the 
people they come into contact with at risk for infection, and potential hospitalization and death. 
Various antivirals such as M2 channel and Neuraminidase inhibitors can help reduce the severity 
of disease, but their efficacy is limited by host of factors including anti-antiviral resistant strains 
of influenza.  
1.2.1 Vaccines  
Currently vaccination is considered to be the most effective way of preventing the spread 
of influenza. However the high mutation rate of the virus necessitates the creation of new 
seasonal vaccines every year. Influenza’s genome is RNA based and its RNA polymerase lacks 
the capacity to proofread the transcripts it produces, allowing for greater number of errors and 
mutations to occur than would with a DNA polymerase. This is propensity for small yet 
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significant mutations to accumulate over time is called antigenic drift. A second type of mutation 
is called antigenic shift and is specific to influenza A viruses only. Influenza’s genome is 
segmented into eight different strands. Should the two viruses from different strains (such as 
H1N1 and H3N2) infect the same cell, segments of genome from the two different strains can 
intermingle, creating new viral strains (such as H1N2) (21).  
 
 
Figure 4. Antigenic Shift and Antigenic Drift. 
 
Because of the high mutation rate of influenza the previous year’s vaccine is reviewed 
and if deemed necessary updated in order to keep up with the strains that are predicted to be the 
most circulating. On a biannual basis the WHO organizes a meeting between representatives of 
national laboratories and research facilities to review surveillance data, clinical studies, and 
laboratory research in order to make recommendations to each country’s public health body and 
vaccine production facilities regarding the formation of the influenza vaccines. Based on these 
meetings the WHO makes recommendations for the specific viruses to be included in the 
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vaccine. In the United States the Food and Drug Administration (FDA) has the final say as to 
which strains of influenza are to be included in the American influenza vaccine (CDC: 
https://www.cdc.gov/flu/about/season/vaccine-selection.htm).  
Vaccines are then produced over a period of five to six months primarily from virus 
grown in fertilized chicken eggs. For those that are allergic to eggs or are unwilling to take a 
vaccine with component from egg grown viruses there are also a class of vaccines produced from 
cell culture grown viruses. According to the CDC there are a variety of trivalent (containing 
three different virus’s components) and quadrivalent (four component) vaccines available to the 
public. The trivalent vaccines include standard and high dose intramuscular shots, as well as a 
vaccine made from cell culture grown virus, and a vaccine made with the adjuvant MF59.  The 
quadrivalent vaccines include both intramuscular and intradermal vaccines, as well as a cell 
culture grown vaccine strains of influenza.  (CDC: 
https://www.cdc.gov/flu/protect/keyfacts.htm). All of these vaccines fall into the category of 
inactivated influenza vaccines (IIV), which are vaccines made from viruses that have been 
chemically inactivated so that they are no longer infectious.   
As of the time of publication there exist a variety of novel vaccine strategies currently 
under research. One such method uses recombinant influenza virus like particles (VLPs) that do 
not require chicken eggs or cells. VLPs share a similar structure to wildtype virus, except they 
lack genomic RNA fragments. VLP’s can infect human and animal cells but cannot replicate 
making them safe to handle and an effective vaccine platform (CDC: 
https://www.cdc.gov/flu/protect/vaccine/how-fluvaccine-made.htm). The surface of influenza 
VLPs can be made to express viral surface glycoproteins such as hemagglutinin and 
neuraminidase. These can then be injected into a patient in the same manner as an IIV, whereby 
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the host’s immune system will develop antibody dependent protective immunity with a 
diminished risk of infection or discomfort to the patient (22). VLPs can be grown in insect cells 
which has a twofold benefit, firstly it provides a vaccine option to those who are unwilling or 
unable to receive egg produced vaccines. Secondly certain strains of influenza, such as highly 
pathogenic H5N1 avian flu, will kill chicken eggs, precluding this system as an effective means 
to generate virus for vaccines (23).  
Though vaccines are readily available to the public, vaccination efforts are hampered for 
a variety of reasons. Mutations within the viral genome necessitate the creation of new vaccines 
every year. The efficacy of each year’s vaccine relies on accurately identifying the strains most 
likely to circulate widely. Yet these predictions are not always entirely accurate, leading to 
reduced vaccine efficacy. The 2014-2015 influenza season provides an excellent example. Total 
vaccine efficacy for that year was only 23%, likely as a result of the H3N2 virus circulating 
through the population being antigenically and genetically different from the A/Texas/50/2012 
(H3N2) vaccine component (24). In order to address the shortcomings of the seasonal vaccine 
certain pharmaceutical therapeutics have been pursued.  
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Table 1 . Current Influenza vaccines available in the United States for 2016-2017 flu season. 
Manufacturing Company Vaccine Name Vaccine Type 
GlaxoSmithKline Fluarix Quadrivalent Quadrivalent, IIV, 
intramuscular, egg grown 
Sanofi Pasteur Fluzone Quadrivalent Quadrivalent, IIV, 
intramuscular, egg grown 
Sanofi Pasteur Fluzone Intradermal 
Quadrivalent 
Quadrivalent, IIV, 
intradermal, egg grown 
Seqirus Afluria Quadrivalent Quadrivalent, IIV, 
intramuscular, egg grown 
Seqirus Flucelvax Quadrivalent Quadrivalent, IIV, 
intramuscular, cell-culture 
grown 
Seqirus Afluria Trivalent, IIV, intramuscular, 
egg grown 
Seqirus Fluvirin Trivalent, IIV, intramuscular, 
with adjuvant, egg grown 
Sanofi Pasteur Fluzone  High-Dose Trivalent, IIV, intramuscular, 
high dose, egg grown 
Protein Sciences Flublok Trivalent, Recombinant 
Influenza Vaccine, 
intramuscular 
Medimmune FluMist Quadrivalent* Quadrivalent, Live 
Attenuated Influenza Vaccine 
(LAIV), intranasal spray 
*Not recommended for 2016-2017 flu season 
 
Based on data from the Centers for Disease Control for the 2016-2017 flu season. 
https://www.cdc.gov/flu/protect/vaccine/vaccines.htm#modalIdString_CDCTable_0 
1.2.2 Antivirals  
Neuraminidase and M2 channel inhibitors are comprised of a number of pharmaceuticals 
that inhibit viral spread within a host. Neuraminidase is an influenza surface molecule which 
promotes daughter virus release from infected cells (25).  Neuraminidase inhibitors like 
oseltamivir (Tamiflu) act as a sialic acid analogue and prevent neuraminidase from cleaving the 
bond between viral hemagglutinin and sialic acid residues on the infected cell’s surface (26, 27). 
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This results in daughter virions aggregating on infected host cell surfaces and reduces viral 
release.  
The Matrix-2 (M2) protein is an integral membrane proton channel that facilitates the 
dissociation of viral nucleoprotein from the matrix protein upon acidification of the endosome 
(28). This step begins the process by which the viral nucleoprotein dissociates with the matrix 
protein of the capsid, eventually resulting in viral genome unpacking (28). M2 channel inhibitors 
like Amantadine prevent the dissociation of the nucleoprotein from the matrix protein by 
inhibiting the ion channel activity of the M2 protein (29-31). M2 is also important in the 
formation of mature hemagglutinin molecules. Viral membrane proteins are translated and 
inserted into the endoplasmic reticulum for transport via the trans-Golgi network. M2 prevents 
over acidification of the Golgi’s lumen, preventing premature conformational rearrangement of 
the nascent hemagglutinin and leading to its inactivation (29, 30, 32).  
Both M2 channel and neuraminidase inhibitors efficacy has been proven clinically; 
reducing length of illness, morbidity, and mortality if taken quickly after the onset of symptoms 
(25, 33-36). However this reduction in symptom intensity and duration is slight (37). While the 
targets of both types of pharmaceuticals are conserved some influenza strains have developed 
resistance, limiting these drugs efficacy (31, 36, 38, 39). The incidence of drug resistance 
appears to be low, and when it does occur usually results in a reduction of infectivity, replicative 
ability, and pathogenicity for the mutant strain (25, 36, 40). Another concern is the lack of data 
indicating that oseltamivir or other antivirals reduces the transmission of virus (37). Clinical 
studies have demonstrated that patients on oseltamivir 24 hours post onset of symptoms can have 
relatively similar viral load counts to un-treated patients (41). These patients might experience 
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relief from their symptoms and feel well enough to return to the community, but remain 
infectious.  
1.3 ANIMAL MODELS OF INFLUENZA  
Various animal species can serve as useful models in understanding how infectious 
diseases infect, propagate, and spread through human populations. They serve as a bridge 
between the divide between in vitro and clinical research. However it is critical to select animals 
that best replicate human physiology, susceptibility, and clinical symptoms, while also taking 
into account practicality. Three such models be discussed, the murine, the nonhuman primate, 
and the musteline.  
1.3.1 Murine Model 
Mice (Mus musculus) have been and continue to be the most widely used model for 
influenza research mainly for reasons of practicality. Mice are small, easy to handle, and are 
relatively cheap to house, maintain, and breed when compared to other established models (3, 
42).  This allows researchers to perform studies with larger sample sizes than are practical for 
other non-murine models. Additionally the wide variety of genetically modified and mutant 
murine strains allows researchers to perform genetic and loss of function studies that other 
animal models would preclude. Additionally there exists a plethora of murine specific reagents 
readily available to researchers that are less plentiful for other animal models. (3). However the 
mouse model is not ideal for influenza research for a variety of reasons.  
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Mice are not a natural host for influenza, and their susceptibility to the virus is dependent 
upon both the strain of the mouse and influenza virus being used (3, 42). Inbred mouse strains 
used commonly in the laboratory setting may lack a functional Mx1 protein, a known antiviral 
factor. These Mx1 negative mice more susceptible to infection with influenza compared to wild 
type mice (3, 43). This can lead to higher infectivity and mortality rates amongst the lab strains 
than would be seen amongst wild type mice or in humans during an actual influenza outbreak.  
Human strains of influenza are not able to replicate as efficiently in mice as they do in 
humans. It may be necessary then to adapt human specific influenza strains to mice by passaging 
the virus through murine cell lines in order to efficiently establish an infection in this model (44, 
45). Additionally mice do not display the same clinical symptoms of influenza infection that is 
seen in humans (45). Mice commonly develop hypothermia during the course of infection, which 
is in direct contrast to the fever that humans commonly display (46). Finally mice have neither 
been known to display the common symptoms seen in humans of coughing or sneezing when 
infected with influenza (42).  
Other issues regarding the use of mice is the lack of sialic acid residues with α-2, 6 
linkage to galactose. Human specific strains of influenza preferentially bind to this complex, 
which is commonly found on the surface of epithelial cells of the human respiratory system. 
Mice do possess α-2, 6 sialic linked receptors, but they are confined to epithelial cells of the 
cecum, rectum, and blood vessels (47). Viral replication and viral induced damage occurs 
primarily in the lower lung of the mouse model, which generally occurs in the upper airways (48, 
49). Finally mice do not easily transmit human specific strains between themselves, 
demonstrating unsuitability for research into viral spread (50). All of these factors diminish the 
suitability of using the murine in influenza research.   
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1.3.2 Nonhuman Primate Model 
Nonhuman primates like Rhesus and Cynomolgus macaques are similar to humans in 
regards to physiology and genetics. This makes them an excellent model compared to genetically 
distant mammalian species like mice, Guinea pigs, and ferrets. Nonhuman primates are 
susceptible to a wide variety of unadapted influenza strains and exhibited similar common 
symptoms, such as fevers, malaise, and nasal discharge (42, 51). Highly pathogenic strains of 
influenza are thought to induce extreme morbidity and mortality through cytokine storms, in 
which an over expression of proinflammatory cytokines results in increased morbidity and death. 
Nonhuman primate are known to react similarly, overproducing cytokines mounting an abnormal 
and less effective immune response (51, 52).  
While nonhuman primates are ideal for their susceptibility to human strains of influenza 
as well as their clinical similarities to humans post infection there are several issues that diminish 
their utility as effective models. Nonhuman primates have complex husbandry requirements, are 
expensive to maintain and house, and are not widely available for laboratory use (42). 
Additionally there are ethical considerations which make working with nonhuman primates a 
tricky and difficult proposition. Finally nonhuman primates carry a wide variety of zoonotic 
diseases that are transmittable to humans who work in close contact with them. Of particular 
concern is Cercopithecine herpesvirus 1 which is readily transmitted by bites, scratches, and 
mucosal contact with infected fluids. While the virus is relatively benign in nonhuman primates, 
zoonotic infectious of humans can results in fatal encephalomyelitis or severe neurological 
damage (53). These considerations make working with nonhuman primates less ideal regardless 
of their suitability as a model for influenza infection. 
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1.3.3 Musteline Model 
Ferrets (Mustela putorius furo) provide an excellent animal model for investigative 
research of the influenza virus, and have been used in this capacity since the 1930’s. Other 
animal models including mice, cats, dogs, guinea pigs, and non-human primates have all been 
used in the past, but ferrets serve as a cost effective model that accurately simulates the course of 
infection observed in humans (3). Ferrets are small to medium sized, easily house, and cared for, 
are relatively inexpensive to study compared to non-human primates, more easily handled, and 
undergo a similar disease course as humans.  
Ferrets are accepted as the best animal model for influenza research. While their larger 
size, limited availability from breeders, and paucity of ferret specific reagents available to the 
scientific community pose significant challenges, ferrets possess unique qualities that make them 
ideal models (50). Ferrets are readily susceptible to human strains of influenza without, 
removing the need to adapt viral strains to this model. Viral transmission and infection in the 
ferret model follows a similar progression as seen in humans. Ferrets present similar clinical 
symptoms as humans, including sneezing, coughing, nasal discharge, fever, and lethargy. The 
size of the ferret can also be preferable as well, bronchial alveolar lavage, blood sampling, and 
tissue collection at necropsy is more substantial (3). Finally and most importantly of all ferrets 
and humans share a similar distribution of ɑ-,6 linkage sialic acid receptors in the respiratory 
tract, which helps explain both the susceptibility to human strains of influenza seen in ferrets (3).  
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1.4 NOVEL PROTEIN BINDERS AS INFLUENZA ANTIVIRALS: HB36.6 AND 
A13R33  
1.4.1 Protein Binder HB36.6  
Prior work performed in Cole laboratory at the University of Pittsburgh’s Regional 
Biocontainment Laboratory (RBL) evaluated the performance of the novel antiviral HB36.6. 
HB36.6 was initially developed by Drs. David Baker and Deborah Fuller at the University of 
Washington, using their computational modeling program Rosetta. HB36.6 was final product of 
several peptides initially designed to bind the highly conserved stem region of the influenza A 
hemagglutinin protein, and screened for improved affinity to a wide variety of influenza A 
hemagglutinin subtypes.  This protein was a mimic of a naturally occurring neutralizing antibody 
whose binding would inhibit fusion of the virus with the host cell, thereby diminishing its 
infectivity and ultimately neutralizing the virus (54).  
HB36.6 was generated by modification of its predecessor, HB36.5, where HB36.5 was 
subjected to random mutagenesis of its nucleotide sequence and a library of peptides was 
created. Each peptide’s amino acid residues were individually mutated to all other possible 
amino acids, and the library of generated peptides were sequenced. Enrichment or depletion of 
each individual mutation during affinity maturation was evaluated and a new library was 
constructed consisting of the most optimal substations in the amino acid sequence. Yeast cells 
displaying hemagglutinin from Influenza A/South Carolina/1/1918 H1N1 were used in two 
rounds of sorting, and a peptide with nine substitutions, referred to as HB36.6, was selected. 
HB36.6 was confirmed to preferentially bind to the stem of hemagglutinin (Figure 5A-C), to 
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possess high affinity (Figure 5D), and to demonstrate comparable equilibrium binding constants 
(Figure 5E) against select hemagglutinin subtypes.  
 
Figure 5. Characterization of HB36.6. 
(A) Crystal structure of A/South Carolina/1/1918 (H1N1) hemagglutinin protein. (B) PR8 hemagglutinin 
bound to HB36.6. (C) Hemagglutinin protein from A/South Carolina/1/1918 (H1N1) (blue) with HB36.6 
(cyan) docked into PR8 in B showing HB36.6 fits well into the stem region regardless of steric hindrance. 
(D) Equilibrium binding constants for HB36.5 and HB36.6 against various hemagglutinins demonstrated 
broad binding of group 1 subtypes. (E) EC50 (μg/ml) (compound concentration that reduces viral 
replication by 50%) of HB36.6, the monoclonal antibody FI6v3, and ribavirin against group 1 and group 2 
viruses. ND = not determined (54). 
 
Once HB36.6 was characterized in vitro, in vivo evaluations using BALB/c mice was 
performed. Mice receiving HB36.6 intranasally in doses ranging from 0.1 to 6mg/kg < 48 hours 
prior to infection with a lethal dose of A/California/07/2009 pH1N1 adapted for mice 
demonstrated 100% survival. Additionally, treated mice exhibited less weight loss compared to 
mice that received no antiviral treatment (Figure 6A, B). Only 20% of mice that received the 
lowest dose of 0.01/kg < 48 hours prior to infection survived (Figure 6B). Protection was also 
confirmed with two additional strains of influenza, A/Puerto Rico/8/1934 H1N1 and 
A/Duck/Minnesota/1525/1981 H5N1 following treatment with 3mg/kg of HB36.6 2 hours before 
infection. (Figure 6C) (54). 
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Figure 6. HB36.6 provides prophylactic protection against lethal influenza challenge in BALB/c mice. 
Survival curves and weight change in (A) BALB/c mice treated with 6mg/kg HB36.6 intranasally at 2, 24, 
and 48 hours before challenged with 10 times mouse lethal dose 50% (MLD50) CA/09 H1N1. (B) BALB/c 
mice administered 0.01, 0.1, or 1.0 mg/kg dose of HB36.6 intranasally 2 hours prior to challenge with 10 
MLD50 CA/09 H1N1. (C) BALB/c mice that received 3.0mg/kg HB36.6 intranasally 2 hours prior to 
infection with 10 MLD50 CA/09 H1N1, 6 MLD50 H1N1 A/PR/8/34 (PR8), or 3 MLD50 
A/Duck/MN/1525/81 H5N1 (MN81). Note n=10 per group for Figures A and C, n=5 per group for Figure 
B (54). 
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1.4.2 HB36.6 Evaluation in Ferrets 
Our laboratory group expanded upon the in vitro characterization and mouse studies by 
evaluating the efficacy of HB36.6’s in the ferret model. Ferrets were chosen for these studies as 
they better recreate both the physiological conditions found in humans as well as the clinical 
symptoms post infection. The first study measured HB36.6’s prophylactic efficacy based upon 
dose. Two sets of ferrets were administered HB36.6 2 hours prior to infection.  The first group 
(n=4) received 2.5mg/kg of HB36.6 and the other group (n=4) received 10mg/kg. A third control 
group (n=4) did not receive any HB36.6 at all. Animals were challenged with 
A/California/07/2009 pH1N1 and the results of the experiment can be seen in Figure 7 below. 
Daily core temperatures in Celsius (Figure 7A) and weight change (Figure 7B) were monitored 
and recorded for all animals. Additionally a scoring system based on clinical symptoms and their 
severity was used to monitor the ferrets, with a higher score corresponding to a greater degree of 
illness (Figure 7C) (55). See Appendix A for clinical scoring sheets used to evaluate symptoms. 
Three days post infection all animals were euthanized and necropsied 
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Figure 7. Clinical signs of disease in ferrets treated with low doses of HB36.6 and untreated control 
ferrets after aerosol exposure to A/California/07/09 (H1N1). 
Three groups of ferrets (n=4, per group) were either administered 2.5m/kg of HB36.6, 10mg/kg of HB36.6, 
or nothing 2 hours before challenge with 2.6 x 107 TCID50 A/California/07/09 2. (A) Temperature (°C) of 
treated and untreated control ferrets over the course of infection. (B) Percentage of weight change of treated 
and untreated control ferrets over the course of infection. (C) Individual ferret clinical scores for treated and 
untreated control ferrets over the course of infection. Graphs A and B are shown with mean and SD at each 
time point. Graph C is shown with mean at each time point. Statistical analysis was done using a two-way 
ANOVA for multiple comparisons where ɑ = 0.05 (55). 
 
Ferrets treated with HB36.6 demonstrated no differences in temperature (Figure 6A).  
Treated ferrets on average lost more weight than the untreated controls, however, the weight loss 
was not significant (Figure 6B). Interestingly, clinical scoring among the three groups 
demonstrated significance (Figure 6C).  Treated animals had fewer and less severe clinical signs 
of disease compared the untreated controls (Figure 6C). This suggested that HB36.6 was able to 
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reduce clinical signs of disease either by reducing the amount of virus replication or by reducing 
the immunological damage induced in vivo.    
To address the quantitative measure of virus present in all three groups of ferrets 
following challenge, nasal washes were obtained daily and lung tissue harvested at necropsy.  
These samples were analyzed by quantitative polymerase chain reaction (qPCR) to determine the 
quantitative level of virus present in each sample.  In order to calculate the titer of the virus, viral 
loads were to a viral standard curve generated from serially diluted RNA extracted from 
A/California/07/2009 pH1N1 RNA. Virus from daily nasal washes (Figure 7A) and lung tissues  
(Figure 7B) are shown below (55). 
 
 
Figure 8. Viral loads from daily nasal washes and homogenized lungs in ferrets treated with low dose 
HB36.6 and untreated controls after aerosol exposure to A/California/07/09 (H1N1). 
Three groups of ferrets (n=4, per group) were either administered 2.5m/kg of HB36.6, 10mg/kg of HB36.6, 
or nothing 2 hours before challenge with 2.6 x 107 TCID50 A/California/07/09 2. Viral loads were measured 
by semi-quantitative reverse-transcriptase RT-PCR following aerosolized pH1N1 infection in (A) nasal 
wash, and (B) lung tissue at necropsy. All data is represented with the mean at each time point. Statistical 
analysis on nasal wash data was performed using a two-way ANOVA for multiple comparisons (55). 
 
Viral loads for untreated controls were higher on days 1 and 2 post infection (Figure 8A). 
HB36.6 treated ferrets demonstrated reduced viral loads in a dose-dependent manner. Similarity 
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lung homogenates from HB36.6 treated ferrets showed reductions in viral load in a dose-
dependent manner and compared to untreated controls (Figure 8B). These data suggested that 
HB36.6 was able to bind and inhibit virus infection in vivo in the ferret model.  Given that the 
first study was only allowed to proceed for 3 days, corresponding to the approximate time of 
peak infection for this challenge virus in the ferret model (previous experience, unpublished 
data), additional studies following the ferrets clinically for up to 7 days post infection were 
performed. (55).  
The second study was interested in evaluating longer time points post virus challenge and 
evaluating higher concentrations of HB36.6 pre-infection. A second study using higher doses of 
HB36.6 was performed. As before three groups of ferrets were used, however one group (n=4) 
received 20mg/kg of HB36.6 24 hours prior to infection while the second group (n=2) received 
the same dose 2 hours prior to infection. The third group (n=2) remained untreated and served as 
controls. Similar to data obtained for the first ferret study, temperatures, (Figure 8A), weights 
(Figure 8B), and clinical scores (Figure 8C) were monitored daily post influenza infection. Nasal 
washes collected daily (Figure 9A) and lungs harvested at necropsy (Figure 9B) were analyzed 
for viral loads (55).  
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Figure 9. Clinical signs of disease in ferrets treated with high doses of HB36.6 and untreated control 
ferrets after aerosol exposure to A/California/07/09 (H1N1). 
This study consisted of two untreated control ferrets, two ferrets treated with 20mg/kg HB36.6 two hours 
before infection with H1N1, and four ferrets treated with 20mg/kg HB36.6 24 hours before infection. 
Ferrets were challenged with 2.6 x 107 TCID50 A/California/07/09. (A) Temperature (°C) of treated and 
untreated control ferrets over the course of infection. (B) Percentage of weight change of treated and 
untreated control ferrets over the course of infection. (C) Clinical scores of treated and untreated control 
ferrets over the course of infection. Graphs A and B are shown with mean and SD at each time point. Graph 
C is shown with mean at each time point (55). 
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Figure 10. Viral loads from daily nasal washes and homogenized lungs in ferrets treated with high dose 
HB36.6 and untreated controls after aerosol exposure to A/California/07/09 (H1N1). 
This study consisted of two untreated control ferrets, two ferrets treated with 20mg/kg HB36.6 two hours before 
infection with H1N1, and four ferrets treated with 20mg/kg HB36.6 24 hours before infection. Ferrets were 
challenged with 2.6 x 107 TCID50 A/California/07/09. Viral loads were measured by semi-quantitative reverse-
transcriptase RT-PCR following aerosolized pH1N1 infection in (A) nasal wash, and (B) lung tissue at necropsy. All 
data is represented with the mean at each time point. Statistics were not performed due to sample size of n=2 for 
some groups (55). 
 
Ferrets treated with the higher dose of HB36.6 24 hours prior to infection lost almost as 
much weight as the untreated controls (Figure 8B). This is a marked contrast to the ferrets treated 
with HN36.6 2 hours prior to infection. Interestingly though both the treated and untreated 
animals showed a continuous downward trend in weight loss over the lengths of the study. While 
the clinical scores of the treated ferrets were much lower than the untreated controls, they 
remained high over the course of the study, especially when compared back to the clinical scores 
of the first study. Treated ferrets from the first study were never given a clinic score of 30, while 
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on day 4 of the second study the two ferrets given HB36.6 2 hours prior to infection scored over 
30. Based on observations, we hypothesized that the higher dose of HB36.6 might be toxic to the 
ferrets and may have led to an increase in the clinical scores. Upon initial observation, it 
appeared that the viral load data conflicted the first study. However, this was not the case as the 
ending time point for measurement of viral loads in the lung tissue were different. For example, 
study 1 measured day 3 post infection compared to the second study which measured up till day 
6.  This explains the fall in the peak range of viral load after challenge (Days 3-4) and 
demonstrated a marked difference in treated (lower) vs. untreated (higher) ferrets.  In contrast, 
when measuring viral loads at day 7 post challenge, the treated ferrets demonstrated higher viral 
loads while the untreated ferrets had lower viral loads. The latter is to be expected, as innate and 
adaptive immune responses generally begin to clear virus from the lungs over time.  In the 
treated animals we hypothesized that the virus that was not completed reduced by the initial 
treatment with HB36.6 was lagging behind the initial challenge, and by day 7 had the 
opportunity to replicate in the lung. Thus, the day 7 data demonstrated a ‘lag and catch up’ of 
viral loads in the treated animals.  A more detailed study of daily viral loads in multiple tissues 
will be warranted along with immune responses to further tease this apart. However, this general 
trend can be observed in the longitudinal nasal wash samples in this second study (55).  
Together, these two studies demonstrated the efficacy of HB36.6 in blunting the early 
virus infection in the ferret model, supporting the in vitro and in vivo mouse data obtained by the 
University of Washington. Studies to minimize toxicity of the binder would be needed to move 
this product into clinical trials.  
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1.4.3 Minibinder A13r33 
To further address the limitations on use of long peptide HB36.6, including but not 
limited to difficulty in production, cost, solubility, and potential toxicity in vivo, the Baker and 
Fuller labs began development of MiniBinders. These are smaller peptides than the antivirals 
(such as HB36.6) that were tested previously. These new peptides contain the biologically 
relevant portion of the original peptides. These mini-binders were shown to be more flexible in 
solution, more soluble, and would be less expensive to generate given their smaller size. Smaller 
size would also result in even less immunogenicity that the first generation binders like HB36.6.   
To date animal studies have demonstrated that low doses (0.3mg/kg) of A13r33 given 
prophylactically are more effective in preventing weight loss and death in BALB/c mice 
compared to an equal dose of HB36.6 (Figure 10). A13r33 displays a higher binding constant 
(K0) to A/Puerto Rico/8/34 H1N1 than both HB36.6 and monoclonal antibody F16. Furthermore 
a lower concentration of A13r33 is required to reduce viral replication by 50% (EC50) when 
compared again to HB36.6 and F16 (Table 2). All of this suggests that A13r33 might be a more 
effective in controlling influenza infection than other antivirals tested in the past.  
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Figure 11. A13r33 provides greater prophylactic protection against lethal influenza challenge in 
BALB/c mice. 
Survival curves and weight change comparison in BALB/c mice treated prophylactically with 0.3 mg/kg 
HB36.6, 0.3 mg/kg A13r33, or negative control.   
 
 
 
Table 2. Comparison of HB36.6 to A13r33. 
 
 
Equilibrium binding constants (K0) for HB36.and A13r33 against various against A/PR/8/1934. EC50 
(μg/ml) (compound concentration that reduces viral replication by 50%) of HB36.6, the monoclonal 
antibody FI6, and A13r33 against A/PR/8/1934 and A/CA/7/2009 
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2.0  STATEMENT OF PROJECT AND AIMS 
During the 2015-2016 flu season the CDC estimated that over 300,000 people were 
hospitalized in the United States for flu related illness (CDC: 
https://www.cdc.gov/flu/about/qa/hospital.htm). As has been mentioned before influenza is 
responsible for the deaths of tens of thousands of Americans through both direct and indirect 
means, as well as costs tens of billions of dollars lost to hospitalizations, treatments, and lost 
work hours each year (12, 13). Currently vaccines are considered to be the best direct protection 
against the influenza virus. Accurately identifying the strains likely to circulate most widely is 
difficult and can lead to vaccines that provide little to no protection against more pathogenic 
strains. To combat this difficulty a variety of antivirals have been developed, but their success 
has been varied. Influenzas strains resistant to oseltamivir and other influenza antivirals has 
already been observed (31, 36, 38, 39). Worryingly some strains continue to exhibit resistance to 
antivirals after the selective pressure have been removed (56). Oseltamivir is known to only 
slightly decrease the time between onset and alleviation of symptoms, while providing moderate 
relief. Additionally viral loads in treated versus untreated patients do not differ much 24 hours 
post onset of symptoms, which calls into question the drug’s efficacy (41). Finally oseltamivir is 
known to cause a plethora of side effects including nausea, headaches, and renal and psychiatric 
syndromes (37).  
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It is for these reasons that new antiviral drugs should be pursued for the sake of the 
public’s health. This project, based upon prior work conducted both at the University of 
Washington as well as the University of Pittsburgh seeks to evaluate A13r33, a novel antiviral 
peptide. A13r33 is similar to a previously tested antiviral, HB36.6, in that both bind to viral 
hemagglutinin and interfere with virus-cell fusion. Unlike HB36.6 A13r33 binds with greater 
efficiency to two different strains of H1N1 and potentially neutralizes the virus at a smaller dose 
(Table 2). A13r33 also binds to influenza strains with a better efficiency than the F16 
neutralizing antibody, which can bind to 16 hemagglutinin subtypes (57). Additionally we knew 
from prior work that animals treated with HB36.6 exhibited a reduction in the severity of clinical 
symptoms associated with infection (58). Based on this information we developed the following 
hypothesis: A13r33 would be effective at both reducing the viral loads and reducing the clinical 
signs of disease following aerosolized infection with pandemic H1N1. To test this hypothesis 
two aims were developed using ferrets infected with A/California/07/2009 p H1N1. 
2.1 AIM 1 
To demonstrate efficacy of the novel computationally designed antiviral minibinder 
A13r33 against influenza infection with A/California/07/2009 pH1N1 in the ferret model 
through analysis of clinical symptoms. 
All ferrets used in these studies were monitored and scored daily with a detailed clinical 
scoring system developed by Dr. Kelly Cole and Dr. Deborah Fuller. Prior to infection all of the 
ferrets that were used in the study were weighed, their temperatures were taken, and clinical 
scores were collected. This data was used as a baseline of comparison allowing our research 
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group to compare the ferrets retrospectively between pre- and post-infection. Following infection 
with aerosolized virus weights, temperatures, and clinical scores were collected daily up till and 
including the day the animals were sacrificed. 
2.2 AIM 2 
To characterize the virological and immunological correlates of protection of 
A13r33 in the ferret model following exposure to aerosolized challenge with pandemic 
H1N1 influenza. 
Viral titers were determined by extracting influenza genomic RNA from nasal washes 
and homogenized lung samples. To calculate viral loads from nasal washes, a one-step reverse 
transcription quantitate polymerase chain reaction (RT-qPCR) was employed to evaluate samples 
collected both pre-infection and one to seven days after infection. These were compared back to 
standard curve generated from RNA extracted directly from A/California/07/2009 pH1N1 grown 
in the lab with chicken eggs. Viral titers in the lung were calculated using a two-step RT-qPCR 
procedure. The first step generated cDNA from extracted RNA and the second analyzed the 
cDNA.  
Viral titers are commonly associated with disease severity, and that high viral loads can 
lead to an overresponse of the host’s immune system (59, 60). This overreaction further leads to 
hyper production of proinflammatory cytokines, inventively referred to as a ‘cytokine storm.’ 
Thusly this project sought to quantify the amount of virus to see if a) A13r33 treatment reduced 
viral loads and b) if viral loads corresponded to the severity of clinical scores.  
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2.3 SUPPORTING EXPERIMENTS 
An additional experiment performed in a group of six male ferrets prior to work with 
A13r33. The purpose of this experiment was twofold. Firstly we sought to identify if an altered 
strain of A/California/04/2009 H1N1 (CA/09-NLuc) virus modified to express luciferase within 
the polymerase subunit (PA) was usable for our future experiments (61, 62). The virus was 
reported to image through the skin and tissues of animals using an In Vivo Imaging System 
(IVIS) from Perkin Elmer. This would allow us to view infection as it spread through the animal 
of the entire time course of infection without the need of sacrificing the animal. Our second goal 
was to identify which routes of challenge with virus, aerosol or intranasal, would lead to a 
representative model of influenza infection.  
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3.0  MATERIALS AND METHODS 
3.1 BIOSAFETY 
Influenza A H1N1 is classified as a biosafety level (BSL) 2 pathogen by the Centers for 
Disease Control (CDC). In accordance with established guidelines, work with the live virus was 
performed in a class II biosafety cabinet (BSC). Given the airborne transmissible nature of 
influenza, and H1N1 in particular, the University of Pittsburgh has established guidelines that 
require the additional use of Individual respiratory protection in the form of powered air 
purifying respirators (PAPRs) or N95 particulate respirator masks to be worn by all researchers 
and staff (63). Individuals working in a cell culture lab must don a liquid barrier gown, two pairs 
of gloves and eye protection prior to commencing work with virus in the BSC.  When working 
with animals in the vivarium, individuals must don a full Tyvek, bouffant caps, disposable water-
resistant shoe covers (double layered), double gloves and respiratory protection.  To minimize 
aerosolized transmission of virus or cross-contamination among animal cohorts, all animals were 
triple housed in HEPA filtered isolator containment cages with locking doors (Allentown, PA). 
All equipment in the vivarium, including BSCs, surgical equipment, glass/ plastic-ware, pipettes, 
reagent bottles, etc. were decontaminated with a 1% Wescodyne® Germicidal Detergent 
(STERIS Corporation, cat # NJ138). All equipment in the BSL 2/ 2+ facilities where in vitro 
work was performed was decontaminated with a 10% bleach solution followed by 70% ethanol 
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solution. All work was performed in the laboratories and vivarium of the Center for Vaccine 
Research at the University of Pittsburgh. All facilities were inspected and monitored at least 
annually by the Department of Environmental Health and Safety and the Division of Laboratory 
Animal Resources.  
3.2 VIRUS PROPAGATION 
A stock of influenza virus, A/California/07/2009 H1N1, obtained from Biodefense and  
Emerging Infectious Research Resources Repository (BEI Resources) (BEI Resources cat #: 
NR13663) was used to infect specific pathogen free (SPF) fertilized chicken eggs obtained from 
Charles River Laborites in May of 2016. Eggs were incubated at 100°F and about 60% humidity 
for 11 days in a GQF Sportsman 1502 incubator. Eggs were candled in order to identify the main 
vein and the air sac of the egg. A mark was made on the shell on the side furthest from the vein 
and a hole was punched through the shell with a 1 inch 18 gauge blunt needle embedded in a 
rubber stopper. Virus was inserted via a tuberculin syringe with a 1 inch 23 gauge needle at 
approximately 2.3*108 TCID50/ml.  Eggs were incubated for 40-48 hours prior to placing at 4°C 
overnight. Virus was then harvested from the allantoic fluid of each egg, which was clarified by 
centrifugation at 2000 rpm x 10 min before making 1 ml aliquots for storage at -80C. A virus 
titer of 2.3*108 was confirmed by tissue culture infectious dose 50 (TCID50/mL) using Madin-
Darby Canine Kidney Epithelial cells (MDCK). See Appendix C for TCID50 calculation method.  
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3.3 TISSUE CULTURE INFECTIOUS DOSE 50% 
TCID50 assays measure the amount of virus necessary to infect and kill 50% of the cells 
present in a given culture. TCID50 assays are performed using tissue culture, however a similar 
assay using chicken eggs can be used in lieu. If eggs are used instead the assay is called a 
Chicken Egg Infectious Dose 50% assay (CEID50). It is important to note that these two assays 
are only able to measure viral particles that are able to infect tissue cells or chicken eggs. They 
do not quantify all non-infectious virus particles that are present, which are still capable of 
causing an immune response. For these studies, TCID50 assays were performed using Madin 
Darby Kidney (MDCK) cells, a cell type commonly used for in vitro influenza work. 
Confluent T75 or T150 cell culture flasks containing MDC cells were exposed to 2 or 
4mL of Trypsin respectively and the cells were enumerated using a dyeing agent (Trypan blue). 
The cells were plated at a concentration of 3 – 4 *105 cells/mL. 100μL /well of resuspended cells 
were pipetted into 96 well flat-bottom cell culture-treated plates. Cells were placed in an 
incubator at 37°C with 5% CO2 overnight prior incubating with samples to be titered. The first 
dilution was added to the top row in quadruplicate at a 1:10 dilution, and serial 10-fold dilutions 
were performed down the plate.  Negative controls (no virus) and positive controls (samples with 
known titer at a specific dilution as well as media/virus only) were included in each plate. Plates 
were incubated for 4 days then scored for cytopathic effect as determined by loss of monolayer 
in each well by light microscopy.  The TCID50 was calculated using the formula for Reed and 
Muench.     
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3.4 AEROSOL INOCULATION 
All animals used in this study were exposed to aerosolized H1N1 influenza virus via a 3-
jet Collison nebulizer (BGI, INC). The nebulizer was housed inside an airtight class III BSC 
(Baker Co.) maintained under negative pressure, and was controlled by a an AeroMP bio-aerosol 
exposure system (Biaera Technologies) (64). This device creates a uniform aerosol of particles 1 
to 2 µm in size, allowing the ferrets to inhale these particles more deeply into their lungs and 
preventing the entirety of the virus from depositing onto the surfaces of the upper respiratory 
tract.  
Ferrets were placed into exposure cages in the animal holding room and transported to 
the aerosol suite in HEPA filtered rodent transport boxes provided by the University of 
Pittsburgh’s Division of Laboratory Animal Resources (DLAR).  Ferrets were placed into the 
mobile transport cart which was attached to a Class III Glovebox containing the aerosol 
equipment.  Once inside, the transport cart was sealed, the exposure cages with the ferrets inside 
were individually removed from their transport boxes and placed into the Class III Glovebox via 
a pass-through door.  All ferrets were placed into the exposure chamber and exposed to 
aerosolized H1N1 for 10 minutes followed by a 10 min air wash to remove any residual virus 
that may be remaining on their fur.  Following the aerosol exposure, ferrets were moved back 
into the transfer cart, placed back into their transport boxes and the boxes wiped with 1:128 
solution of Vesphene (STERIS Corporation, cat#: 646108).The transport boxes were then 
removed from the aerosol line, and the ferrets returned to the vivarium. An all glass impinger 
(AGI) containing 10 mL of viral growth media was used to collect the influenza virus. The 
presented dose was calculated by using Guyton’s Formula of Vm = 2.1 + Wb0.75, where Wb is the 
weight of the animal, to find the respiratory minute volume (Vm). Multiplying Vm by the length 
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of exposure gives the total volume of experimental atmosphere inhaled (Vt). Multiplying Vt by 
the aerosol concentration (Ce) gives the presented dose. Three experiments were performed as 
part of this thesis: 
1. Comparison of intranasal vs. aerosol pilot infection (infection date 5/2016) 
2. Prophylactic study 1 (aerosol date 4/18/2017) 
3. Prophylactic study 2 (aerosol date 5/5/2017) 
For the first study conducted in May of 2016, modified A/California/04/2009 H1N1 (a 
generous gift from Dr. Stacey Schultz-Cherry of St. Jude Children’s Research Hospital was used. 
Viral titers for this study were as follows, 104.45 TCID50/ mL for animals infected via aerosol or 
104.2 TCID50/ mL infected via intranasal inoculation. See section 3.5.1 for further explanation of 
this experiment.  For A13r33 study, the first group that was aerosolized on April 18th had an 
average presented dose of 3.9*106 TCID50/mL was calculated. The second group aerosolized on 
March 5 had an average presented dose of 4.05*105 TCID50/mL. See section 3.7 for further 
explanations of this portion of the study.  
3.5 FERRETS 
All ferrets were purchased from Triple F Farms through the University of Pittsburgh’s 
Division of Laboratory Animal Resources (DLAR). Ferret sera were screened via 
hemagglutination inhibition assays and determined to be H1N1 sero-negative ferrets prior to 
acquisition (see Appendix A for how these assays  are performed). DLAR monitored the clinical 
health of the animals, provided food, water, enrichment, and care. All ferrets were acclimated for 
72 hours prior to any experimental manipulation per Institutional Animal Care and Use 
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Committee (IACUC) protocol. The University of Pittsburgh abides by all federal regulations 
governing the use of animals in research in the U.S. and is an Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) accredited institution. All procedures were 
approved by the University of Pittsburgh’s IACUC.   
Ferrets were acclimated for a minimum of 48 hours prior to any manipulation by 
members of the Cole lab. All animals then were anesthetized for implantation of microchips, 
which were used to facilitate identification and temperature readings.  Baseline weights and 
temperatures were obtained, as well as pre-bleeds and baseline nasal washes obtained prior to 
influenza infection. Twenty four hours prior to infection, selected ferrets received mini-binder 
via intranasal or intra-tracheal administration (5 mg/kg) as designated. Control animals received 
nothing. Following aerosol challenge with influenza, all ferrets were monitored daily: weights, 
temperatures, clinical scoring, and collection of nasal washes. The clinical assessment was 
developed by Drs. Cole and Fuller, and details the physical, respiratory, neurological and 
intake/output for each study ferret.  A copy of the clinical assessment scoring sheet is shown in 
Appendix A. 
i. Sedation of Ferrets.  For blood draws and nasal washes, all ferrets were sedated 
with 2-5% isofluorane and 4-10% oxygen via anesthesia box or face mask. Total 
sedation was determined by observing a reduction of the animal’s respiratory rate, 
lack of tone or tensing of the muscles in the neck and upper body, as well as by 
administering a toe pinch to the hind legs. Following procedures, all ferrets were 
monitored until fully awake and alert prior to placing back into their caging.  As 
needed, ferrets were placed on a warming cloth to assist with recovery from 
sedation, 
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ii. Implantation of IPTT-300 Microchip.  Following the 48 hour acclimation 
period a subcutaneous IPTT-300 microchip (BioMedical Data Systems, cat # 
2145251) was inserted between the scapulae of the animals. The microchip was 
programmed to provide the ferret ID, and allowed for easy identification of the 
ferrets as well as measured the ferret’s core temperature using a DAS-7006/7r 
handheld wireless scanner (BioMedical Data Systems, Inc.). 
iii. Blood Draw.   
iv. Nasal Wash.  Ferrets were sedated with isofluorane prior to flushing 1 ml sterile 
1X phosphate-buffered saline (PBS) (Gibco) through the nostrils to collect a nasal 
wash. For the procedure, ferrets were placed in a supine position with their head 
tilted down and slightly on an angle to one side. A pipette or syringe with the 
volume of PBS placed so the tip was situated at the nares of the ferret. The liquid 
was then flushed gently through one nostril as it was observed coming out of the 
other nostril.  Liquid was recovered into a petri dish, stored into a 2.0 ml freezing 
vial and stored at -80°C.  A notation was made with regard to how congested and 
full of mucous each sample/animal presented.   
v. Necropsy: See Section 3.8 
3.6 VIRAL INFECTION ROUTE STUDY 
Prior to any work with A13r33 was performed, a small study using a modified strain of 
influenza gifted to the Cole lab by Dr. Stacey Schultz-Cherry of St. Jude Children’s Research 
Hospital. A/California/04/2009 H1N1 virus was a modified strain of influenza using an eight 
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plasmid 293T/MDCK co-culture system to express a 19-kDa engineered luciferase within the 
polymerase subunit (61, 62). Male ferrets 10 -12 weeks of age were acquired and injected with 
subcutaneous temperature/ identification chips. Ferrets were divided into groups and were 
challenged with CA/09-NLuc either via aerosol or intranasal inoculation, with control animals 
(n=2) remaining uninfected. Infected animals (n=2) were given 10e4.45 TCID50/ mL via aerosol 
or 10e4.2 TCID50/ mL via intranasal inoculation (n=2). Nasal washes were collected daily 
following infection up till the time of necropsy. Additionally on days 1 and 3 IVIS imaging was 
performed using an IVIS Spectrum In Vivo Imaging System (Perkin Elmer, part # 124262). On 
day 3 all animals were euthanized with 200mg/kg of Euthosol. Once death was confirmed, soft 
palate, nasal turbinates, trachea, right and left lung tissue samples were harvested. Fresh tissue 
samples were collected into RNA later for viral and immunological analyses, while samples for 
pathological studies were fixed in formalin. All work was performed at BSL 3 in the Regional 
Biocontainment Laboratory (RBL) due to the location of the IVIS. 
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Figure 12. Timeline of viral challenge comparison between aerosolization versus intranasal injection 
studies with CA/09-NLuc in the ferret model. 
Six ferrets were used in this stud. Animals in the infected group (n=4) were challenged with a modified 
strain of A/California/04/2009 H1N1 which expresses a luciferase within the viral polymerase subunit.  
Ferrets were challenged either with 104.45 TCID50/ mL of virus via aerosol (n=2), 104.2 TCID50/ mL via 
intranasal inoculation (n=2), or remained unchallenged as negative controls (n=2).  
  
3.7 MINIBINDER FERRET STUDY 
Two groups of nine ferrets each were received for this study, separated by a period of 
three weeks. The first group was aged 10 to 12 weeks and weighed an average of 350 grams. The 
second group were between 10 to 12 weeks of age and weighed on average 450 grams. One day 
prior to exposure to aerosolized H1N1 three animals from the group were given an intratracheal 
dose of 5 mg/kg of minibinder via a laryngoscope. A cannula was used to inoculate the carina, 
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which is the portion of the trachea directly above the bronchial branches of the lungs, with the 
minibinder. This procedure was performed by a DLAR veterinarian to ensure the safety and 
comfort of the animal. Three other ferrets in the same grouping were administered a dose of 5 
mg/kg of minibinder intranasally via a micro-pipette. The last three animals of the group were 
kept as untreated controls and were administered nothing. All nine animals in each group were 
challenged with pandemic H1N1, 2.3 *108 TCID50/mL and received an average aerosolized dose 
of 3.9*106 TCID50/mL (first group) 4.05 *105 TCID50/mL (second group) or of virus. Nasal 
washes and clinical scoring was performed for seven days following exposure. On the seventh 
day after the clinical scores and nasal washes were collected the animals were euthanized and 
necropsied.  
 
 
Figure 13. Timeline of A13r33 prophylactic study in the ferret model. 
Nine ferrets were challenged with 2.3*108 TCID50 pandemic A/California/07/2009 H1N1influenza virus. 
One day prior to infection three animals were given 5 mg/kg of minibinder intratracheally and three were 
given 5 mg/kg of the same drug intranasally. Three animals were left untreated as controls.   
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3.8 NECROPSY 
Seven days after the ferrets were exposed to aerosolized pandemic H1N1 influenza virus, 
all animals were euthanized. The ferrets were first sedated with isoflurane, ranging from 2-5% 
depending upon previous experiences with the individual animals as well observations of 
breathing rate and muscle tone. The footpads of the hind legs were pinched hard, if a reaction 
was observed the animal was left under sedation. Nasal washes were collected quickly while the 
ferrets were still sedated. For the first set of nine animals a heart stick to collect blood was 
performed immediately after the nasal wash.  A VanishPoint® 1mL syringe with a 27 gauge ½ 
inch needle was used to capture the blood samples. For the second group of animals it was 
decided that a heart stick would prove too difficult to accurately perform with the ferrets 
increased size. The method of blood collection used for the second group is detailed below. The 
ferrets were then put under sedation again until they no longer responded to a toe-pinch. The 
ferrets were then euthanized with an intraperitoneal injection of Euthasol at a concentration of 
200mg/kg into the lower left quadrant of the abdomen. Following the injection the ferrets 
breathing and heart-rate were monitored until the ceased. Additionally cyanosis of the tissues, 
especially those of the mouth (palates, gums, and lips) was used to confirm death.  
Once the ferrets were confirmed to have been euthanized, the carcass was moved into a 
class II BSC and placed onto an absorbent pad. For the first set of animals the nose was cut off 
using a pair of sharp surgical scissors. This was done to facilitate easy access to the nasal 
turbinates, which were removed with forceps. First the inside of the nasal cavity was scrapped 
with a single tong of the forceps in a vigorous manner. Then the forceps were used to pull tissue 
from the nasal cavity. Next a scalpel to make an incision from the clavicle to the lower abdomen 
and a pair of surgical scissors was used to cut the sternum of the ribs, exposing the lungs and 
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heart. These along with the trachea were carefully removed, and a section of trachea was taken. 
Pieces from the left and right lungs were taken as well and kept separate. Finally a bronchial 
alveolar lavage (BAL) was performed. 10mL of sterile 1x PBS was inserted into the lobes of the 
lungs via a 10mL syringe with a cannula attached to it. Once all lobes had been inflated, the 
syringe was then used to siphon the PBS as well as mucus and other debris out of the lungs. The 
BAL was then placed in a 5mL tube and flash frozen in a dry ice/ ethanol bath. The lungs and 
heart were then placed in a sealed plastic container containing a 10% formalin solution. The lung 
pieces, trachea section, and nasal turbinates were stored in 15 mL conical tubes containing 
around 3 mLs of RNAlater (Thermo Fischer Scientific). The BAL samples were later stored at -
80°C, the lungs, nasal turbinates, and trachea were stored at room temperature for a week before 
being moved to a 4°C fridge. The lung and heart were transferred to new containers containing 
10% formalin and left at room temperature.  
The procedure for the second set of animals was similar to the first, with a few slight 
changes. After the nasal turbinates were collected and the chest and abdomen sliced open, the 
diaphragm was then cut. A 5 or 10mL syringe with an 18 gauge needle was then used to pierce 
the heart and collect the blood sample. The sample was then subdivided, with half of the blood 
injected into Vacutainers coated with 5.4mg EDTA (Becton, Dickson and Company). The 
vacutainers were then spun down in a centrifuge at 1200 rpm for 10 minutes, the serum was 
pipetted off and stored in cryovials at -80°C. The other half of the blood was injected into a 
PAXgene blood RNA tube (PreAnalytiX, cat #: 762165 (BD)). The PAXgene tubes were then 
stored directly at -80°C. Next the celiac artery that feeds blood into the spleen was nicked. A 
gauze pad was placed over this incision to absorb the blood, and the carcass was left alone for a 
few seconds to allow for most of the remaining blood to drain. The rest of the procedure 
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remained the same as that performed on the first set of animals except for the collection of the 
BAL. A 10mL syringe containing 10mL of 1x PBS was used to wash the inner surface of the 
lungs. Once the lobes were inflated the lungs were inverted over a petri dish and the BAL was 
allowed to flow into it. This was then collected and flash frozen via the method explained earlier 
in this section. Nasal turbinates, sections of lung from the right and left sides, and pieces of the 
trachea were also collected and stored in the same manner as described before.   
3.9 TISSUE HOMOGENIZATION 
Sections from the lobes of the right and left lung as well as trachea sections were 
homogenized in order to analyze viral load. Between 100 and 300mg of tissue were weighed in 
50mL conical tubes. A volume of Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% 
Fetal Bovine Serum (FBS) equal to 10 times the mass of the tissue in milliliters was added to the 
tissue sample. The samples were then homogenized using an Omni TH-01 tissue homogenizer 
with an attached 7mm x 110mm tip set to the highest speed, around 35,000 rpm (Omni       
International). Cellular and tissue debris was then centrifuged out by spinning the homogenates 
at 1500 rpm for 10 minutes. Supernatants were transferred to cryovials, which were stored at -
80°C. 
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3.10 RNA EXTRACTIONS 
RNA was isolated from both nasal washes and tissue homogenates using a Trizol/ 
chloroform reaction followed by using either the QIAamp Viral RNA Mini Kit (Qiagen cat. 
#52904/ 52906) or the RNeasy Mini Kit (Qiagen cat. #74104), respectively. 100µL aliquots of 
nasal washes from days 0, 1, 3, 5, and 7 and 100µL aliquots of homogenized trachea were used 
in the extraction. Additionally 50µL aliquots of homogenized right and left lung fragments taken 
from the same ferret were combined into one aliquot, which was then likewise extracted.   
3.11 RT-QPCR  
3.11.1  RT-qPCR for Viral Titers 
After the RNA extractions were performed a one-step Real Time-Quantitative 
Polymerase Chain Reaction (RT-qPCR) was performed using SuperScriptR III PlatinumR One-
Step qRT-PCR Kit with ROX (Invitrogen, cat. #11745100). Amplification and analysis was 
performed on a QuantStudio 6 Flex Real-Time PCR System (ThermoFisher). Influenza A 
specific probes and primers used to detect the viral genome came from the BEI resources 
Influenza Virus Real-Time RT-PCR Assay Kit (BEI Resources NR-15592). See Appendix A 
Table 4 for primer and probe sequences. 
A viral standard curve was used to compare the viral loads taken from the nasal washes 
and lung homogenates. A/California/07/2009 H1N1 virus grown in eggs and with a TCID50 of 
2.3*108 was extracted using the QIAamp Viral RNA Mini Kit and serially diluted in ten-fold 
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increments from 10-1 to 10-8 in nuclease free water. The virus used to create the standard curve 
came from the same stock as that used to initially infect the ferrets. Each PCR run included 
samples of RNA extracted from animal tissues and nasal washes and the serially diluted viral 
RNA. R2 values of > 0.95 were used to calculate the amount of virus present in each sample.  
A master mix of forward and reverse primers, Superscript Taq polymerase mix, 2X PCR 
mix, and nuclease free water was made for each run, see Appendix A Table 5 for master mix 
formula volumes per reaction. 20μl of master mix was pipetted into a MicroAmpR Optical 96-
Well Reaction Plate (Applied Biosystems™, Life Technologies, Thermo Scientific, cat. 
#4306737). 5μl of sample taken from RNA extracted from homogenates/ nasal washes 
(experimental samples) or from virus (viral curve samples) was then pipetted into the appropriate 
wells and the plate sealed with  MicroAmp™ Optical Adhesive Film (Applied Biosystems™, 
Thermo Scientific, cat. #4311971). The reaction plate was then placed into the QuantStudio 6 
qPCR machine and run at the following parameters: 
Step 1: Reverse Transcription, 50°C for 30 minutes 
Step 2: Taq Inhibitor Activation, 95°C for 2 minutes 
Step 3: PCR Amplification (40 cycles) 
Denature, 95°C for 15 seconds 
Anneal, 55°C for 30 seconds 
 
3.11.2 RT-qPCR for Ferret Cytokines  
RT-qPCR for the detection of cytokines in ferret tissue homogenates was performed in a 
two-step process. First cDNA was generated from extracted RNA with the Maxima First 
Strand cDNA Synthesis Kit for RT-qPCR (ThermoFisher, cat # K1642) using a 
PTC-200 Thermocycler (MJ Research). 5X Reaction mix, Maxima Enzyme Mix, and 
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nuclease free water were mixed together into a master mix. See Table 6 in Appendix A for the 
formulation of this master mix. 15μl of master mix and 5μl of RNA extracted from homogenates 
were mixed together in 0.2mL flat cap PCR tubes. Note mass of template RNA was between 1pg 
and 5μg. Tubes were then loaded into the Thermocycler, which was run at the following 
parameters  
 Step 1: Incubation, 25°C for 10 minutes 
 Step 2: Amplification, 50°C for 15 minutes 
 Step 3: Reaction termination, 85°C for 5 minutes 
 
Next quantitative PCR was performed using the Maxima SYBR Green/ROX qPCR 
Master Mix (2X) (ThermoFisher, cat # K1642) < 500ng template cDNA. As with the 
aforementioned viral titer RT-qPCR, amplification and analysis of the cDNA product was 
performed on a QuantStudio 6 Flex Real-Time PCR System (ThermoFisher). Ferret specific 
primers targeting cytokines of interested were manufactured by Integrated DNA Technologies, 
sequences for those primers can be found in Appendix A in Table 7. A master mix of forward 
and reverse primers, Maxima SYBR Green/ROX qPCR Master Mix, and nuclease free water was 
made for each run, see Appendix A Table 8 for master mix formula volumes per reaction. 20μl 
of master mix was pipetted into a MicroAmpR Optical 96-Well Reaction Plate (Applied 
Biosystems™, Life Technologies, Thermo Scientific, cat. #4306737). 5μl of sample taken from 
RNA extracted from homogenates was then pipetted into the appropriate wells and the plate 
sealed with MicroAmp™ Optical Adhesive Film (Applied Biosystems™, Thermo Scientific, cat. 
#4311971). The reaction plate was then placed into the QuantStudio 6 qPCR machine and run at 
the following parameters: 
Step 1: UDG pre-treatment, 50°C for 2 minutes 
Step 2: Initial denaturation, 95°C for 10 minutes 
Step 3: PCR Amplification, (40 cycles) 
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Denature, 95°C for 15 seconds 
Anneal, 60°C for 30 seconds 
Extension, 72°C for 30 seconds  
 
After cytokines were successfully detected expression levels of cytokines were 
normalized to the house keeping gene Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). 
ΔΔCt to determine fold change was used to determine the fold change in cytokine expression. 
First the QuantStudio 6 measures the rate of amplification in each well, and once a certain limit 
of fluoresce is detected (above background fluoresce provided by ROX) a Ct value is assigned. 
Subtracting GAPDH Ct values from experimental Ct values gives the change in threshold cycle. 
(ΔCt). Fold change is then calculated by subtracting the day 0 ΔCt from the subsequent days ΔCt 
values. Finally the formula 2-ΔΔCt is used to obtain the absolute value for fold change (65).  
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4.0  RESULTS  
4.1 PROJECT OVERVIEW 
The goal of this project was to complement work performed by our collaborators at the 
University of Washington’s on novel influenza antivirals. While their work was built around the 
mouse model of infection we sought to include the ferret model which better represents infection 
and disease progression in humans. This study sought to evaluate the efficacy of a novel protein 
minibinder (A13r33) to limit infection and disease following prophylactic treatment 24 h prior to 
virus challenge when administered either directly into the carina of the lungs or intranasally. 
Previous work from the Cole lab evaluated the efficacy of an earlier version of A13r33 (a larger 
protein binder, HB36.6) and demonstrated differences in clinical disease progression and viral 
loads following influenza infection when comparing treated and untreated ferrets. The present 
study was designed to further evaluate A13r33 mini-binder for its efficacy against influenza 
infection when administered prophylactically.  The following sections will describe results from 
the preliminary ferret studies to compare intranasal and aerosolized influenza infection in ferrets, 
generation and characterization of the virus stock needed to perform these studies, and the 
pivotal study to evaluate A13r33 or its ability to protect against influenza in ferrets.  
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4.2 GENERATION OF REAGENTS NEEDED FOR STUDIES 
4.2.1 Generation of Egg Grown Virus  
One of the first critical steps in this project was to generate a large amount of high titer 
virus stock that could be used for all ferret and cell culture studies to insure minimal variation 
between each portion of the studies. To accomplish this, 30 day 10 SPF chicken embryos were 
inoculated with our seed stock of pH1N1 (from the BEI repository). Virus was allowed to 
propagate for 48 hours at 100°F, 60% humidity. At 48 hours, all eggs were placed in sealed egg 
cartons at 4°C overnight to stop the infection.  The following day, the allantoic fluid containing 
the virus was harvested from each egg and combined. This solution was clarified by 
centrifugation and the virus stock was aliquoted for storage at -80C.   
 
 
 
Figure 14. Day 13 Harvest of allantoic fluid from fertilized chicken eggs. 
Allantoic fluid was harvested from fertilized chicken eggs 13 days after they had arrived in lab and 2 days 
after being inoculated with A/California/07/2009 pH1N1 
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4.2.2 TCID50 to Determine Viral Titer  
TCID50 assays using MDCK cells were performed in order to quantify the titer of the 
virus that had been grown in the SPF chicken eggs. See Figure 21 in Appendix A for the layout 
of a standard TCID50 plate. Cytopathic effect on the MDCK cells was observed and recorded, 
results are seen below in Table 3. For further information on how TCID50 calculations are 
performed see Appendix C.  
 
Table 3. Raw Data of Observed Cytopathic Effect used to determine TCID50 of egg grown 
A/California/07/2009 pH1N1.  
Dilution Positive Wells Negative Wells % Death 
10-1 4 / 4 0 / 4 100% 
10-2 4 / 4 0 / 4 100% 
10-3 4 / 4 0 / 4 100% 
10-4 4 / 4 0 / 4 100% 
10-5 4 / 4 0 / 4 100% 
10-6 4/ 4 0 / 4 100% 
10-7 1/ 4 3 / 4 25% 
10-8 0 / 4 4 / 4 0% 
10-9 0 / 4 4 / 4 0% 
10-10 0 / 4 5 / 4 0% 
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4.3 PILOT FERRET STUDY TO COMPARE VIRUS CHALLENGE ROUTE 
Six male ferrets (n=2 per group) were received for a pilot study to compare the early 
onset of infection following aerosol versus intranasal infection with a modified strain of 
A/California/04/2009 pH1N1 that encodes luciferase. Two ferrets were left as uninfected 
controls. The purpose of this pilot study was to compare the early infection and to the standard 
clinical, virological and immunological monitoring as well as the possibility of using IVIS (CT) 
to monitoring early events post infection. 
4.3.1 Temperatures 
Temperatures (°C) for infected ferrets were collected daily after challenge with influenza 
virus, as well as a few days prior to challenge (Figure 15). Temperatures for uninfected ferrets 
were not taken. Both groups of infected animals exhibited little change in temperature over the 
time course of the experiment, however this is likely due to the short duration of time between 
viral challenge and sacrifice.  
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Figure 15. Temperature comparison between ferrets infected via aerosol or intranasal routes. 
Two groups of ferrets (n=2/ group) were infected with a modified strain of A/California/04/2009 pH1N1 
that produces luciferase in its polymerase protein. Ferrets challenged via aerosolized virus (circles) 
received 104.45 TCID50/ mL, ferrets challenged by intranasal injection (triangles) received a titer of 104.2 
TCID50/ mL. Control animals (data not shown) were not un-infected Statistics not performed due to low 
sample size. 
 
4.3.2 Weight Loss Percentage  
A small amount of weight gain was observed for both the uninfected controls and the 
ferrets that were challenged intranasally with virus (Figure 16). Ferrets that were challenged via 
aerosol exhibited a consistent weight, until day 3. At this time point both ferret in this group 
exhibited some weight loss, however the results do not appear significant. It is unclear if this 
weight loss would have continued or been significant, due to the short duration of this study (3 
days) and the small sample size of ferrets (n=2/ group).  
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Figure 16. Calculated weight loss percentage of ferrets infected via aerosol or intranasal routes 
compared to uninfected controls. 
Two groups of ferrets (n=2/ group) were infected with a modified strain of A/California/04/2009 pH1N1 
that produces luciferase in its polymerase protein. Ferrets challenged via aerosolized virus (circles) 
received 104.45 TCID50/ mL, ferrets challenged by intranasal injection (triangles) received a titer of 104.2 
TCID50/ mL. Control animals (squares) were not infected. Statistics not performed due to low sample size. 
4.3.3 Clinical Scores   
Clinical scores for all animals were observed over the duration of the study (Figure 17). 
Control animals did not see virus and as expected demonstrated no signs of disease.  Ferrets 
infected with A/California/04/2009 pH1N1 via the intranasal route exhibited only minor signs of 
disease, including some nasal or ocular discharge, occasional coughing or sneezing, and were 
slightly less playful than they had been prior to infection.  In contrast ferrets infected via the 
aerosol route exhibited higher clinical scores due to more severe signs of disease, including 
lethargy, reduced appetite and mucous in their stool, some dehydration, piloerection, coughing, 
sneezing, and ocular and nasal discharge. Since the study was only carried out to day 3, it is 
unclear whether the intranasally challenged ferrets were only delayed in their disease or whether 
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the overall disease course was different based on route of infection.  Further studies are needed 
to tease this apart.  
 
 
Figure 17. Clinical Scores of ferrets challenged either via aerosolized or intranasally instilled 
influenza compared to uninfected controls. 
Two groups of ferrets (n=2/ group) were infected with a modified strain of A/California/04/2009 pH1N1 
that produces luciferase in its polymerase protein. Ferrets challenged via aerosolized virus (circles) 
received 104.45 TCID50/ mL, ferrets challenged by intranasal injection (triangles) received a titer of 104.2 
TCID50/ mL. Control animals (squares) were not infected. Statistics not performed due to low sample size. 
4.3.4 Viral Titers in Nasal Washes and Select Tissues  
Sections of the soft palate, the trachea, nasal turbinates (Figure 18A), and right and left 
lungs (Figure 18B) were taken from each animal at necropsy. Nasal washes were collected from 
animals on a daily basis by injecting 1mL of 1X sterile PBS into the nares of the ferret and 
allowing it run through the nasal cavity and out the other nostril (Figure 18C). TCID50 assays 
were performed on MDCK cells to quantify the amount of virus in each sample. Interestingly, 
despite differences in clinical scores by day 3 post infection, there were little difference in the 
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titers of virus regardless of the route of viral entry into the ferrets. Nasal wash titers were also 
similar between the aerosol and intranasally challenged ferret groups (Figure 15C).  
 
 
Figure 18. Viral Titers of A/California/04/2009 in various tissues and nasal washes measured by 
TCID50. 
Ferrets were infected via the indicated route and sacrificed 3 days post infection (DPI). From these animals 
the specified tissues were harvested. Nasal washes were also collected from each animal, sterile 1x PBS 
was injected via syringe into the nose and allowed to drain out. (A) Data is presented in TCID50/mL. n = 2 
ferrets/ group. (B) Data is presented in TCID50/g. n = 2 ferrets/ group. (C) Nasal wash viral titers, data is 
presented in TCID50/mL. n = 2 ferrets/ group. Graphs are shown as averages of the 2 animals TCID50 
values. Statistics not performed due to low sample size. 
4.3.5 Summary of Study  
In general both intranasal and aerosol H1N1 challenge of ferrets resulted in infection and 
disease in the ferret model.  Interestingly, despite similar levels of virus within 3 days post 
challenge, there were marked differences in clinical signs of disease and the severity of 
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symptoms presented between the two infected cohorts. Further studies analyzing the 
immunological and pathological differences between animals infected by either route are 
necessary to understand the differences in observed symptoms. Additionally longer period of 
time between infection and sacrifice should also be considered. This will help confirm if the 
intranasally infected ferrets lagged behind the aerosol group in regards to the displayed 
symptoms or if this route of virus introduction is less efficient at establishing an infection.  
4.4 A13R33 STUDY: AIM 1 
For all figures in this section (Figure 16 through 18) ferrets that received the minibinder 
intranasally are represented by red symbols (n=6). Blue symbols represent those ferrets that 
received the minibinder via the intra-tracheal route (n=6). Control ferrets are represented by 
green symbols (n=6) and received no antiviral minibinder. All animals were challenged with 
A/California/07/2009 pH1N1 24 hours after A13r33 was administered. Ferrets represented by 
open figures (Study 1) were challenged with a viral load equal to 3.9*106 TCID50/mL. Ferrets 
represented by shaded figures (Study 2) were challenged with a viral load equal to 4.05*105 
TCID50/mL.  
 
Restatement of Aim 1: To demonstrate efficacy of the novel computationally 
designed antiviral minibinder A13r33 against influenza infection with A/California/07/2009 
pH1N1 in the ferret model through analysis of clinical symptoms. 
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4.4.1 Temperature  
Observations of animals were made in the morning over a seven day period following 
infection with pH1N1 Ca/09, as well as on a day prior to infection with the virus. Temperatures 
in degrees Celsius (°C) were collected via a subdermal transponder inserted between the 
scapulae of each animal. The transponder was injected on day 01, the same day that the first 
nasal wash, clinical score, weight, and temperature was collected. Twelve out of the eighteen 
ferrets used in this study were administered a single 5mg/kg dose of A13r33 minibinder 24 hours 
prior to infection with pandemic influenza virus. The antiviral minibinder was administered via 
either intranasal or intra-tracheal routes to the designated ferrets in the two treated groups. Figure 
12 below details the observed results of this portion of the study. The black line represents the 
mean of all the ferrets within the specified groups: intranasal, intra-tracheal, and control. Open 
figures represent ferrets challenged with 3.9*106 TCID50/mL TCID50/mL of virus, while shaded 
in figures represent ferrets challenged with 4.05*105 TCID50/mL TCID50/mL. The data suggests 
that the titer of the virus used in the challenge had little impact on the temperature trends. All 
groups show an increase in temperature two days post infection, however the mean of the 
intranasally dosed ferrets did not spike as highly or as rapidly as the intra-tracheal or control 
ferrets. Ferrets that received A13r33 intranasally had their temperature return to baseline by Day 
5 (Figure 19A). Ferrets in the intratracheal cohort appear to return to baseline by day 7 (Figure 
19B). Interestingly the control group’s average temperature plateaus between days 3 and 6, but 
then exhibited a day 7 increase, which was unseen in the two treated cohorts (Figure 19C). 
                                                 
1 Note: Day 0 occurred at least three days after the ferrets arrived in the vivarium, allowing them time to settle and 
acclimatize to the new environment. Additionally Day 0 was at least 24 hours prior to the ferrets receiving their dose 
of A13r33. This spread out the number of invasive procedures performed on each animal and allowed for better 
observations of their health as it was affected by viral challenge and administration of the antiviral.  
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Figure 19. Temperatures of ferrets treated prophylactically with A13r33 compared to control 
untreated ferrets. 
(A) Temperatures of ferrets that received A13r33 intranasally with either a micropipette or syringe. (B) 
Temperatures of ferrets that received an intra-tracheal dose of A13r33 via a cannula inserted through the 
mouth.  (C) Temperatures of untreated control ferrets. Note that temperatures for F-007 and FT-009 were 
not taken for day 0 due to issues with the subdermal transponders.  All graphs are shown with a black line 
denoting the mean for the respective group.  
4.4.2 Weight Loss Percentage 
Weight loss for ferrets in this study became noticeable within two days of aerosolized 
challenge with pandemic H1N1, and exhibited a general levelling off by day 3. Of all group in 
this study the ferrets that were administered A13r33 intranasally exhibited the most significant 
loss in weight as seen on day 3 of Figure 20A. Both intra-tracheal (Figure 20B) and control 
animals (Figure 20C) exhibited much less weight loss, with neither group losing more than 5% 
of their starting body weight. Another interesting trend is that the two treated groups (intra-
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tracheal and intranasal demonstrated a general increase in body weight between day’s 6 and 7. 
Control animals displayed a plateauing of their average weight over the same period of time.  
 
 
Figure 20. Calculated weight loss percentage of ferrets treated prophylactically with A13r33 
compared to control untreated ferrets. 
(A) Weight loss percentage of ferrets that received A13r33 intranasally with either a micropipette or 
syringe. (B) Weight loss percentage of ferrets that received an intra-tracheal dose of A13r33 via a cannula 
inserted through the mouth.  (C) Weight loss percentage of untreated control ferrets. All graphs are shown 
with a black line denoting the mean for the respective group.  
4.4.3 Clinical Scores  
In order to quantify the clinical symptoms of infection a scoring system was developed 
prior to this study. Researchers at the Universities of Pittsburgh and Washington assigned 
numerical values of 2, 5, and 10 to a variety of symptoms (see Appendix A). Symptoms were 
recorded and the results tallied, giving a final score for the observed ferrets. Figure 14 below 
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details the results of this scoring system. There appears to be a correlation between the titer of 
virus received and the severity of illness exhibited. Ferrets challenged with a higher TCID50 of 
pandemic H1N1 generally exhibited higher clinical scores. Control ferrets exhibited the highest 
clinical scores of all groups, and remained sicker for longer than the two treated groups (Figure 
21C). Between days 1 and 2 after infection their average clinical score increased more rapidly 
when compared to the two treated cohorts. Interestingly the intranasal cohort exhibited two 
different peaks based on the titer of virus received. Animals challenged with a higher titer of 
virus peaked earlier on day 3 compared to the peak seen on day 5 for the cohort exposed to the 
lower titer of virus. By day 7 both the intranasal (Figure 21A) and intra-tracheal (Figure 21B) 
dosed ferret groups had returned to a score of 7 or 13 respectively (average score), compared to 
the controls which remained closer to 20 (again average score).  
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Figure 21. Clinical Scores of ferrets treated prophylactically with A13r33 compared to control 
untreated ferrets. 
(A) Clinical scores of ferrets that received A13r33 intranasally with either a micropipette or syringe. (B) 
Clinical scores percentage of ferrets that received an intra-tracheal dose of A13r33 via a cannula inserted 
through the mouth. (C) Clinical scores percentage of untreated control ferrets. All graphs are shown with a 
black line denoting the mean for the respective group.  
4.5 A13R33 STUDY: AIM 2 
To quantitate the level of virus in ferrets treated with A13r33 with untreated controls, 
one-step RT-qPCR was performed on nasal washes and homogenized lung samples. Each RT-
PCR reaction plate was run with serially diluted viral RNA extracted directly from the egg 
grown stock of A/California/07/2009 pH1N1. Using the equation for the standard curve 
generated by the QuantStudio 6TM, the viral titers were calculated.  
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Restatement of Aim 2: To characterized the virological and immunological 
correlates of protection of A13r33 in the ferret model following exposure to aerosolized 
challenge with pandemic H1N1 influenza. 
4.5.1 Viral Titers  
This portion of the study was designed to evaluate A13r33’s efficacy in reducing viral 
shedding by measuring the viral load present in daily nasal washes taken from all ferrets. Viral 
titers were highest in nasal washes taken 1 day after infection and interestingly the ferrets in the 
second group (Figure 22B) who received a lower titer of virus via aerosol when compared to the 
first group (Figure 22A) had higher titers of virus in their nasal washes. Lung homogenates were 
collected from sections taken from the right middle and left lower lobes of the ferrets’ lungs. 
Viral loads for all lung homogenates were practically identical, regardless of the route of drug 
administration, the presence or absence of the antiviral minibinder, or the titer of virus received. 
Figures 22 E and F show viral loads taken from ferret tracheas (n=2/ group). Ferrets given 
A13r33 intratracheally appear to have a have on average a lower viral titer compared to the 
animals that were given the minibinder intranasally (Figure 22E). However the trachea samples 
from the second group show a higher viral load for the intratracheally treated versus the 
intranasally treated (Figure 22F). If both groups are combined it appears that the average of the 
viral titers for both treated groups are around the same, and lower than the viral titers for the 
untreated controls. Results appear to indicate that route of administration of antiviral played no 
major role in reducing the viral loads in the nasal washes or the lung and trachea samples.  
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Figure 22. Quantification of viral loads in nasal washes and lungs in ferrets prophylactically treated 
with A13r33 after challenge with A/California/07/2009 pH1N1. 
Ferrets in the prophylactic study were treated with 5 mg/kg A13r33 delivered either intranasally or 
intratracheally.  Control animals were not administered A13r33 but were challenged with virus along with 
the ferrets that received the antiviral minibinder. Viral loads taken from homogenized lungs came from 
sections taken from the right middle and left lower lobes. (A) Viral loads in ferret group 1 after exposure to 
3.9*106 TCID50/mL, n=3/ group. (B) Viral loads in ferret group 2 after exposure to 4.05*105 TCID50/mL, 
n=2/ group. (C) Viral loads taken from homogenized lung sections from group 1 after exposure to 3.9*106 
TCID50/mL, n=3/ group. (D) Viral loads taken from homogenized lung sections from group 2 after 
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exposure to 4.05*105 TCID50/mL, n=3/ group. (E) Viral loads taken from homogenized trachea sections 
from group 1 after exposure to 3.9*106 TCID50/mL, n=2/ group. (D) Viral loads taken from homogenized 
trachea sections from group 2 after exposure to 4.05*105 TCID50/mL, n=2/ group. 
 
 69 
5.0  RESULTS 
The ferret studies performed using both HB36.6 (Allison Brichacek) and A13r33 (current 
thesis) support prior studies in the mouse model demonstrating the prophylactic efficacy in 
reducing clinical disease and blunting initial virus burden of initial infection. As had been 
demonstrated prophylactic administration of either peptide is not completely sterilizing in 
regards to high dose aerosol infection. This makes it unlikely that either peptide will provide 
sufficient protection against influenza mediated disease and infection when used alone. 
However, these studies are promising and warrant further evaluation. For example, if it is 
possible to effectively blunt the initial viral load so that patients do not succumb to severe 
disease, additional therapeutics or vaccines in combination with this treatment may be 
successful. Given the broad spectrum efficacy of the minibinder demonstrated in both mouse and 
ferret models, it is likely that this prophylactic will be of great interest as a long term product. 
The need for novel antivirals that are effective in controlling a wide array of influenza subtypes 
is extremely desirable compared to the need to generate a new vaccine each season.  Future 
studies evaluating A13r33 need to include drug titrations, evaluation of timing for prophylactic 
administration pre-infection for efficacy, and the therapeutic efficacy of mini-binder post 
infection. This last study design is extremely important to validate A13r33’s potential as a 
therapeutic to the public at large, and would allow how long post infection the peptide is 
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protective. Together these studies will provide critical insight into the efficacy of this novel 
peptide in protecting from pre- and post-exposure prophylaxis.  
Viral titers in the nasal washes and lung homogenates appear the same between the 
various cohorts regardless of treatment with A13r33 route of minibinder treatment (Figure 19). 
Further analysis will be necessary however if this phenomenon is still observed across all 
dosages of A13r33 or is specific to only the dosage of 5mg/kg. Additional studies with larger 
sample sizes will also be necessary. A concern regarding the current influenza antivirals 
available to the public is that they do not appear to have much effect on the amount of virus shed 
by the infected (35, 66). This is a public health issue as certain antivirals, like oseltamivir, can 
relieve symptoms and make patients feel better more quickly after symptoms start. But these 
individuals who are seemingly recovered still shed virus and can infect others in the community 
without realizing it (41). In order to improve on this deficiency new antivirals need to not only 
control the clinical symptoms of infection but also control viral replication and shedding in the 
host.  This group of mini-binders appears to possess both properties and should be further 
evaluated for its ability to reduce transmissibility post challenge. 
Both HB36.6 and A13r33 demonstrated by the Fuller Lab as binding to and interfering 
with the replication of a wide variety of influenza A subtypes (Figure 5D-E, Table 2). This type 
of broadly effective antiviral is of great importance in the protection of the public from naturally 
arising seasonal and pandemic strains. Protection of troops from exposure by bioweapons and 
civilians targeted by bioterrorists is another potential application for broadly neutralizing like 
these two antivirals. An antiviral drug that does not require refrigeration and is stable at a wide 
range of temperatures, that can be aliquoted into a single dose for easy self- delivery such as 
through an oral or nasal spray, and that can be administered yet effective whether administered 
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just prior to or after the exposure would be the most ideal and desirable product. Given that 
weaponized influenza would be deployed in aerosol form, and the ease by which influenza can 
be acquired and modified to generate more pathogenic strains that do not necessarily exist in 
nature makes the possibility for a widespread influenza exposure a concern for both public health 
and national defense (67). Further development of a product that could blunt the initial exposure 
and reduce the overall disease burden would limit the number of critically ill patients and 
mortalities, reduce strain on hospitals and clinics, reduce the financial burden of care, and 
hopefully reduce the period of transmissibility in the infected post exposure.  Each of these 
scenarios needs to be evaluated in the ferret model as proof of concept so that the mini-binder 
may be moved forward into clinical trials. 
Given the differences in clinical scoring between treated and untreated cohorts (Figure 
18), with insignificant differences in viral loads (Figure 19), further immunological analyses are 
warranted to determine the level to which the immune response (i.e., cytokine storm, pathology, 
etc.) may have contributed to the clinical signs of disease observed. Based on these results, we 
hypothesize that the intranasally administered A13r33 coated the upper respiratory tract of the 
ferrets, thereby limiting the foothold of the virus in this region of the respiratory system. Ferrets 
that had minibinder intratracheally administered more likely had higher concentrations of 
minibinder in the deeper portions of their lungs when compared to the intranasally administered 
ferrets. However ferrets like humans have the highest distribution of ɑ-2, 6 sialic acid linked 
receptors in the upper respiratory tract, which coincidently the region that H1N1 replicates in (4, 
5, 7). This would explain why the intratracheally administered animals displayed greater clinical 
signs of infection than the intranasal cohort, but less severe symptoms compared to the control 
animals. It is also possible that the intratracheal route of administration may have caused 
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irritation or distress to the ferrets. The lag in clinical scores for the intranasal cohort is of some 
interest as well, the peak in clinical signs of infection for this cohort did not occur until day 5. At 
this period of time the other two cohorts appeared to be recovering. One hypothesis is that the 
drug had been reabsorbed by the ferrets at this time, allowing whatever virus had not been 
inactivated to establish an infection. Another hypothesis is that the virus in the intranasal group 
had by this time migrated further away from the higher areas of A13r33 concentration (such as 
the nasal turbinates, upper trachea, and possibly the upper areas of the lung) and was able to 
establish an infection in this area as well. Bioavailability and absorption studies would help 
address which of these proposed scenarios was the cause. Further, it is warranted to evaluate the 
administration of mini-binder alone (no virus infection) in the ferret model to evaluate the 
contribution of the peptide to pathology and immune stimulation.  
5.1 PROPOSED MODEL 
We propose the following model for mechanism of action for A13r33 in the ferret model: 
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Figure 23 Proposed model for prophylactic treatment with A13r33 prior to aerosol challenge with 
A/California/07/2009 pH1N1. 
 
As was mentioned prior we hypothesize that intranasally administered minibinder was 
able to coat the upper respiratory tract, including the nasal turbinates and nasal cavity, the 
pharynx, larynx, and trachea. Intratracheal administration delivered A13r33 to the carina of the 
lungs, likely causing a large volume of the minibinder to bypass the aforementioned 
physiological structures. Aerosolized virus was able then to bind to host epithelial cells in the 
upper respiratory tract in the intratracheal model more readily than in the intranasal model. This 
would explain the differences in clinical scores as ferrets in the intranasal were better protected 
against viral challenge due to the proximity of the antiviral to the site of infection. This could 
also identify the lag to day 5 for the clinical scores in the intranasal cohort to spike (Figure 21A). 
As the virus moved through the respiratory system it would have come into contact with less 
antiviral minibinder, allowing it to more readily infect and replicate in host epithelial cells. 
Intratracheal ferrets had lower clinical scores than controls (Figure 21A, C), but the highest 
clinical score for both groups spiked on the same day. This is likely due to the fact that neither 
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group had enough or any minibinder at the site of infection or the adjoining structures of the 
upper respiratory tract. This would allow the virus to establish an infection more quickly, leading 
the rapid increase in symptoms exhibited by both groups. Further studies to evaluate dosing and 
timing for administration pre- and post-exposure prophylaxis, elicitation of immune responses 
and pathology, and transmissibility of virus in the presence of mini-binder are warranted to fully 
understand the long term efficacy of A13r33. 
5.2 PUBLIC HEALTH SIGNIFICANCE 
Influenza is responsible for widespread illness and death each year worldwide. In 2003 
influenza was responsible for causing and around 22,000 to 25,000 deaths as well as estimated 
cost of over $87 billion in the United States alone (12, 13). With issues of reduced vaccine 
efficacy, emerging influenza strains that are antiviral resistant, as well as issues of logistics, side 
effects, and a public that is increasingly turning against vaccinations, there exists a pressing need 
for effective antivirals that can interact and interfere with a broad variety of influenza strains. 
Certain strains of influenza, such as H5N1, are too pathogenic to be grown in chicken eggs, 
making vaccine production more difficult for these strains (23). H5N1 has also been shown to 
become readily pathogenic and transmissible in the ferret model (67). It is quite possibly that 
H5N1 or other highly pathogenic influenza strains might naturally evolve to become more 
readily infectious in humans while retaining their lethality. In such an event broadly neutralizing 
antivirals will be necessary to combat the potential pandemic.  
Small molecules, like HB36.6 and A13r33, may be best way to provide protection against 
influenza strains. Smaller molecules are less likely to lead to an immune response while 
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providing protection against infection. They are also more likely to interact more discretely than 
larger molecules (68). Since influenza is made of ten different proteins there are a variety of 
targets to choose in designing proteins. Three proteins, NA, HA, and M2 are all found on the 
surfaces of viral particles. All are required to function properly if the virus is to be infective (M2 
and HA) or spread beyond the initially infected cell (NA). Targeting any of these three proteins 
and disrupting their function could lead to interference or a complete halt to the viral infection. 
Antivirals like the two discussed in this thesis are critical in controlling the spread of influenza 
and providing protection to the public at large. There is a critical need for novel approaches that 
are both safe and effective in preventing the spread of the influenza virus. We hope that work 
like research that went into this thesis will ultimately lead to new antivirals capable of reducing 
the morbidity and mortality caused by this virus.  
5.3 FUTURE DIRECTIONS 
The minibinder A13r33 was designed to interfere directly with the vial hemagglutinin 
molecule, disrupting infection. Viral load data suggests that the virus was still able to replicate 
with little to no observable difference in titer amounts regardless of the route of antiviral 
administration. Additionally treated and untreated animals displayed similar viral load titers in 
both homogenized tissues and nasal washes. However there were clear differences in the 
observed clinical symptoms between all three experimental cohorts. It is possible that the 
minibinder was interacting or interfering with the host’s immune response and quite possibly 
relieving symptoms while not reducing viral load.  
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Cytokine RT-qPCR work was attempted however data was not forthcoming in the pursuit 
of this research project. Future work should therefore focus on comparing certain cytokines, 
including IFN-ɣ, TNF-ɑ, and IL-6, 8 10. These cytokines all play a roles in either pro-
inflammatory or anti-inflammatory responses, suppression of viral replication, or are critical to 
signaling the presence of an infection. Additional work using flow cytometry and pathology 
should be used to analyze host immune cell response to infection in the presence or absence of 
A13r33 or other similar antivirals.  
Finally there were only three animals used per cohort and only two experiments were 
performed. Additionally the control animals that were infected but untreated animals did not 
receive any form of sham control protein (such as lysozyme). In the future all animals should be 
treated either with A13r33/ antiviral or a sham control. Larger sample sizes using more ferrets 
per cohort should also be used. Furthermore only one dose of A13r33 was tested, future tests 
should include different concentrations of minibinder to see how this will affect viral loads as 
well as immune response. Comparison tests of A13r33 against antivirals currently available 
(such as oseltamivir) should also be performed. Finally studies should be performed wherein 
animals treated with the minibinder are left uninfected. This will allow researchers to determine 
if there is an immune response against A13r33.  
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APPENDIX A: PROTOCOLS 
MDCK Cell Line Maintenance 
 
Materials and Reagents  
• Madin-Darby Canine Kidney (MDCK) Cells (ATCC CCL-34) 
o Store in liquid nitrogen until ready to be used.  
• Maintenance Media  
o 500mLDMEM (1X, 4.5 g/L glucose, 4mM L-glutamine) 
o 5mLPenicillin/Streptomycin (10,000 U/mL/ 10,000 µg/ml) 
o 5mLHEPES Buffer (1M stock) 
o  5mLL-gluamine, 200 mM (100X), if needed 
o 25mLHeat Inactivated FBS 
o 5mLSodium pyruvate, if needed (may already be in DMEM) 
• Virus Dilution Media  
o 500mLDMEM (4.5 g/L glucose, 4mM L-glutamine) 
o 5mLPenicillin/Streptomycin ( 10,000 U/mL/ 10,000 µg/ml) 
o 5mLHEPES Buffer (1M stock) 
o 12.5mLBovine Serum Albumin fraction V, 7.5% solution in PBS 
• Viral Growth Media 
o 100mL Virus Dilution Media  
o 100µL 1:1000 2mg/mL TPCK Trypsin (stored in 2µg/mL stock) 
• Trypsin/EDTA, 0.25% 
• 96 well plates (flat, u-, and v-bottomed) 
• 1X Phosphate-buffered saline (PBS) (pH 7.2) 
• Water bath 
• T25, T75, and T150 flasks with vented cap 
• 37°C, 5% CO2 incubator 
• 15mL conical tube 
• Trypan Blue solution, 0.4% (Sigma, cat. #T8154) 
• Hemocytometer 
• 1.5mLcryovials 
• Freezing media (90% FBS/10% DMSO) 
o Fetal Bovine Serum (FBS) (Atlanta Biological, Cat. #S11150) 
o Dimethyl Sulfoxide (DMSO) (Sigma, Cat. #D2650) 
o Freezing Container, 1°C/hour (NALGENE™ Cryo, cat. #5100-0001) 
• 70% Ethanol and 10% Bleach 
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• -80°C freezer 
• Liquid nitrogen storage 
• Microscope  
• Biosafety Cabinet class II  
• Serological pipettes  
 
Cell Propagation 
 
Note: Perform all of these procedures in BSC class II 
1. Thaw cells/ initiate culture 
a. Remove cells from liquid nitrogen and thaw in a 37°C water bath 
b. Resuspend in 10mL Maintenance Media  
c. Centrifuge at 400g for 5 minutes 
d. Remove the supernatant with a pipette and resuspend in 8mL of maintenance 
Media 
e. Pipette cells in media into T25 flask with vented cap 
f. Incubate flask in a 37°C, 5% CO2 incubator until cells are confluent, about 24 to 
48 hours.  
g. Siphon media off with a serological pipette and wash twice with 8-10mL of 1X 
PBS 
h. Add 1mL of trypsin, place flask in 37°C, 5% CO2 incubator until cells lift of the 
plate. May take 15 to 30 minutes   
i. Add 18mL of maintenance media, remove total volume of media and cells and 
transfer to T75 flask.  
2. Regular maintaining and splitting MDCK cells 
Note: Split cells at a 1:10 ratio every 3 to 4 days  
a. Siphon off media in the flask with a serological pipette and wash twice with 
10mL of 1X PBS 
b. Add 2mL of trypsin for T75, 4mL for T150 
c. Place flask in 37°C, 5% CO2 incubator until cells lift of the plate. May take 15 to 
30 minutes   
d. Resuspend cells in a 5:1 ratio of maintenance media to trypsin (8mL for T75, 
16mL for T150) 
e. Siphon 1/10 of the volume into a new flask and add 9/10 volume of fresh 
maintenance media 
f. Place flask in 37°C, 5% CO2 incubator 
3. Freezing cells for Liquid Nitrogen Storage 
a. Once flask reaches 80-90% confluency collect cells using methods elucidated in 
2.a-d 
b. Take 20µL of Trypan Blue and mix well with 20µL of cell suspension in a single 
well of a 96 well flat bottomed plate.  
c. Place hemocytometer on microscope tray, add 10µL of trypan-cell suspension 
mix 
d. Count cells in all four corners of hemocytometer (appear as white dots surrounded 
with a blue halo 
e. Use following formula to determine cell count 
 79 
i. (# of cells/4)*2*104= cells/mL 
f. Resuspend cells in a dilution of ~107 cells/mL in freezing media  
g. Aliquot into 1.5mL cryovials 
h. Place aliquots into freezing vessel indicated for 1°C/hour rate 
i. Place vessel into -80°C freezer 
j. After 48-72 hours transfer vials to LN2 for long term storage 
 
Viral Propagation and Growth 
 
Materials and Reagents 
• Embryonated Chicken Eggs, 9-12 days old 
• Candling Flashlight 
• Needle 23 gauge, 1 inch, imbedded in a rubber stopper 
• Needle 18 gauge, 1 inch 
• Disposable syringe 
• 50ml centrifuge tube with 70% alcohol 
• Sterile forceps 
• Influenza virus 
• Egg Incubator  
• Absorbent pads (diaper) 
 
Protocol 
1. Upon delivery of eggs immediately place in incubator set to 100°C and ~ 60% humidity, 
and turn rocker on 
2. Candle eggs daily 
a. Place candling flashlight on the top of the egg (where the air sac is located) 
b. Look for movement inside the egg, if there are distinct veins that connect the 
embryo to the air sac the egg is considered good.  
c. If there is no vein that connects to the air sac or there are no eggs, the egg is either 
dead or was never fertilized  
3. On Day 11 the eggs are ready to be inoculated 
a. Prepare the virus inoculum: 10-3 to 10-10, 10 eggs per dilution. 
b. Wipe top of eggs with alcohol wipes, let dry, and punch a small hole in the 
eggshell over the air sac using an 18 gauge, 1 inch needle. Make sure to punch 
hole close to fluid, so the needle can reach the fluid, and away from any major 
veins. 
c. Aspirate virus inoculum into 1ml syringe with 23 gauge, 1 inch. 
d. Insert the needle into the hole of the egg, pierce the allantoic membrane (about 
0.5cm deep from egg shell) and inoculate 0.2ml per egg into the allantoic cavity. 
e. Change the syringe and needle when finished inoculating eggs in each tray or if 
the needle touches eggshell. 
f. Discard the syringe into a sharps container and seal the punched holes of the eggs 
with tape. Incubate the inoculated eggs at the appropriate conditions for virus 
strain. H1N1: 37°C, >80%RH humidity for 48 hours 
g. After 2 days of incubation remove the eggs from the egg incubator and candle to 
ensure eggs are still good. 
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h. Chill the eggs by placing them in a refrigerator (4°C) overnight (at least 12 hours) 
or chill at -20°C for 2-3 hours to sacrifice the embryo and harden the blood 
vessels for good fluid harvest. 
i. When the virus is ready to be harvested remove from the fridge. Place eggs on 
absorbent pads in a class II BSC.  
j. Dip the forceps in 70% alcohol to sterilize and peel off the top of the eggshell 
(open up the air sac). Insert the 18 gauge, 1 inch needle downward into the 
allantoic sac. Draw out the clear allantoic fluid and avoid disturbing the blood 
vessel and yolk sac and place in proper container depending on dilution. 
k. Perform Hemagglutination assays to determine infectivity 
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Figure 24. Egg Handling for Influenza Virus Production.  
 
Hemagglutination (HA) and Hemagglutination Inhibition (HAI) Assays 
 
Materials and Reagents 
• Biosafety Cabinet class II  
• V- and u-bottomed 96 well plates  
• Microscope  
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• 15mL conical tubes  
• Eppendorf 1.5mL snap cap tubes 
• Serological pipettes  
• Micropipettes (including multichannel) and aerosol barrier pipette tips 
• 1X PBS 
• Washed Pooled Turkey Red Blood Cells (RBC), 10% in Alsevers (Lampire Biological 
Laboratories, cat# 724908) 
• Virus sample to test (Pandemic A/California/07/2009 H1N1) 
• Serum samples (heat inactivated 56°C for 30 minutes)  
• Reservoir Basins  
 
Assays 
 
Note: All Assays are to be performed in a class II BSC.  
1. Hemagglutination Assay 
a. Make a 0.5% working solution of Turkey RBC 
i. Spin 1mL of RBC at 650 rpm for 5 minutes 
ii. Siphon off supernatant (should be clear or light pink, if red the cells are 
lysed the blood should be discarded) 
iii. Resuspend RBC in 10mL of 1X PBS 
b. Add 50µL PBS to each well of u-bottomed plate  
c. In the first column add 50µL of virus and mix well 
d. Transfer 50µL to the next well on the right and change pipette tips. Mix well and 
repeat until the end of the plate is reached, changing tips each time.  
e. Add 50uL of 0.5% RBC working solution to each well and mix very gently  
f. Leave plate at room for 30 to 60 minutes  
g. Negative results will appear as rounded dots of blood at the bottom of the well, 
positive results as a reddish uniform hazed across the total well.   
h. To find the viral Hemagglutinating Units (HAU) find the end point (the last 
positive dilution before the first negative well. Divide 1 by the dilution (i.e. if the 
dilution is 1:8, divide 1 by 1/8, 1/1/8, 8 is the HAU)  
 
2. Hemagglutination Inhibition Assay  
a. Heat inactive all serum samples in a water bath at 56°C for 30 minutes  
b. Make a 0.5% working solution of Turkey RBC 
i. Spin 1mL of RBC at 650 rpm for 5 minutes 
ii. Siphon off supernatant (should be clear or light pink, if red the cells are 
lysed the blood should be discarded) 
iii. Resuspend RBC in 10mL of 1X PBS 
c. Make a 1.0% working solution of Turkey RBC 
i. Spin 2.8mL of RBC at 650 rpm for 5 minutes 
ii. Siphon off supernatant (should be clear or light pink, if red the cells are 
lysed the blood should be discarded) 
iii. Resuspend RBC in 14mL of 1X PBS 
d. Transfer 50µL of sera to Eppendorf tubes and add 200µL of 0.5% turkey RBC, 
mix well 
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e. Incubate room temperature for 30 minutes, vortexing every 10 minutes at medium 
speed 
f. Centrifuge tubes at 14,000 rpm for 5 seconds  
g. Add 50µL 1X PBS to wells B-H 
h. Add 100µL sera supernatant from centrifuged tubes to row A (preferably in 
duplicates or triplicates) 
i. Serially dilute down the plate 1:2 (take 50µL from A mix well into B and change 
tips, repeat), mix well 
j. Remove 50µL from the final row (row H)  
k. Dilute virus to 4 HAU  
i. For work done in Cole Lab with 5/2016 pH1N1 stock this is a 1:4 dilution 
ii. Dilute 3mLs of virus stock in 9mLs of 1X PBS. This is enough for two 
plates 
l. Starting at row H and working up add 50µL of virus to each well, mixing well, 
and changing tips with each well.  
m. Incubate plate at room temperature for 30 minutes.   
n. Add 50µL of 1.0% turkey RBC to each well, changing tips each time. Mix well.  
o. Incubate plates for ~45 minutes at room temperature 
p. Rounded “buttons” of blood appearing at the bottom of the well are negative, 
meaning there are antibodies present specific to the virus. If no pellet forms but 
there is a hazy reddish color to the media that means there are no antibodies 
specific to the virus present.  
 
Tissue Culture Infectious Dose 50 (TCID50) Assay 
 
Materials and Reagents  
• Viral Growth Media 
• 1X PBS 
• flat-bottomed 96 well plates 
• Serological pipettes and pipettor 
• Wet Ice 
• Sterile reagent reservoirs 
• Multichannel pipette and tips 
Procedure 
1. Prepare MDCK cells from a confluent T-75cm2 flask. 
a. Siphon off media in the flask with a serological pipette and wash twice with 
10mL of 1X PBS 
b. Add 2mL of trypsin for T75, 4mL for T150 
c. Place flask in 37°C, 5% CO2 incubator until cells lift of the plate. May take 15 to 
30 minutes   
d. Resuspend cells in a 5:1 ratio of maintenance media to trypsin (8mL for T75, 
16mL for T150) 
e. Enumerate cell concentration using standard trypan blue staining visualized with a 
hemocytometer. 
f. Dilute cells to 3.0 (or 4.0) x 105 cells/ml in maintenance media  
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g. Dispense 100 µl (3.0, 4.0 x 104 cells) into each well of 96 well flat bottom plates 
h. Incubate at 37°C, 5% CO2 until confluent monolayer is obtained (~24-30 hours). 
i. Remove media from MDCK cells using aspiration. 
j. Wash each well with 200 µl of PBS and remove by aspiration. 
k. Add 180 µl of viral growth media to rows B-H of 96-well sterile v-bottom plates 
using multichannel pipette. 
l. Add 200 µl of virus sample to each of 5 wells for sample 1 (columns 1-5), sample 
2 (columns 6-10) and 200 µl of viral growth media to column 11-12 as non-
infection control. 
m. Using multichannel pipette transfer 20 µl from row A to row B, discard tips. 
n. Mix 10-20 times using swirling tip action and transfer again 20 µl from row B to 
row C, discard tips. 
o. Repeat dilution down the plate. 
p. Incubate plates at 37°C, 5% CO2. 
q. On days 3 and 4 post infection observe cytopathic effects (CPE) and score on a 
TCID50 scoring sheet. Mark well with a “+” if CPE is observed, “-” if no CPE is 
observed. Use negative and positive controls to help determine if CPE is present.   
r. Calculate the TCID50 using the method described by Reed and Meunch (ref) 
 
 
 
Figure 25. TCID50 plate set up diagram. 
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Figure 26. Blank TCID50. 
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Ferret Clinical Scoring Sheet  
 
 
Figure 27. Blank Clinical Scoring Sheet. 
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Tissue Homogenization 
Material and Reagents  
• Cell Maintenance Media  
• Pipettes (5, 10, 25, 50 mL) 
• Pipettor 
• Absorbent pads (“diapers”) 
• Tissue samples in 15 mL or 50 mL conical tubes 
• Scale 
• Cryotubes, Nunc 375418 
• Wescodyne (or other antiviral solution) 
• 70% Ethanol 
• 2x 1 L beaker  
• OMNI tissue homogenizer 
• Hard disposable homogenizer tips, autoclavable bags, OMNI 34750-AC-16 
• Wet Ice 
• Dry Ice  
 
Procedure 
1. Prior to Homogenization 
a. Pre-label at least three or four Nunc cryotubes for each sample.   
b. Prepare a spreadsheet to record sample IDs and organ weight to calculate the 
amount of media needed to prepare a 10% (or 5% or 20%) w/v suspension. 
c. Autoclave homogenizer tips in autoclavable bags. 
d. Samples can be weighed and organized into racks @ -80°C ahead of time if 
necessary. 
2. Day of Homogenization 
a. Clean BSC and prepare beaker of antiviral solution (1% Wescodyne, 10% Bleach, 
etc.), 
b. Prepare a second beaker of 70% ethanol  
c. Lay down absorbent pads to cover the area around the homogenizer, it may be 
necessary to place absorbent pads against the walls of the BSC.   
3. Organize and weigh tissues 
a. Organize the organs to be titered on wet ice starting with the samples anticipated 
to have the lowest virus titer and ending with the samples anticipated to have the 
highest titer of virus. 
b. Weigh tissues to be homogenized and record the weight on a spreadsheet.   
a. If there are multiple pieces of an organ (i.e. sections taken from a lung 
sample) weigh multiple pieces together.  
4. Homogenization  
a. Add cell maintenance media to each tube; a minimum of 1.5 mL is needed 
i. A 10% w/v suspension is adequate for most organs  
1. EXAMPLE:  tissue weighs 0.54 g, add 5.4 mL media for 10% w/v 
suspension 
ii. A 5% w/v suspension is appropriate for small organs like nasal turbinates.  
1. EXAMPLE: tissue weighs 0.12 g, add 2.4 mL media for 5% w/v 
suspension 
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ii. For large tissues such as a ferret brain, a 10% w/v results in a large volume  
1. EXAMPLE: brain weighs 6.2 g, 62 mL will not fit in 50 mL 
conical 
a. Add a set volume of media to grind (10 mL) 
b. Then add enough media to bring up to 20% (10 mL + 21 
mL = 31 mL)  
c. Spin homogenized sample  
d. Put 1 mL of the 20% homogenate into cryotubes and add 1 
mL of media to achieve a 10% w/v suspension and vortex 
well before use 
b. Setup the homogenizer and prepare beakers containing antiviral solution to 
disinfect tips.  Place absorbent pads in the work area. 
c. Homogenize each organ using the tissue homogenizer.  
d. The amount of time needed to homogenize organs varies with the size and 
consistency of the tissue and the speed of the motor. There are six speed levels on 
the OMNI homogenizer and we typically use the maximum (6) speed.  Soft 
tissues such as brain and lungs take less time (~10-20 seconds) than harder tissues 
such as nasal turbinates (~30 sec - 1 minute).  Homogenize until tissue is no 
longer recognizable.  Nasal turbinates will be pulverized but not homogenized. 
e. Before removing the used tip from the grinder, immerse it in a 50 mL conical tube 
containing antiviral solution to disinfect the tip. 
f. Remove the grinder tip and place it in a beaker containing antiviral solution.  Put 
a new grinder tip on the homogenizer and continue until tissues are homogenized. 
g. Wipe down the homogenizer with bleach wipes, especially the on/off switch and 
the tip holder. 
h. Spin the homogenized samples to pellet cellular debris 10 min. at 1500 RPM 
(~524 g) at 4°C. 
i. Organize the cryotubes in racks.  
j. Aliquot 1000 µL (or half the volume if < 2 mL total) of each tissue homogenate 
into duplicate (or more) cryotubes (300 µL minimum needed for titration). 
i. Place one cryotube on WET ICE if titering immediately. 
ii. Place duplicate cryotube(s) on DRY ICE to freeze 
Add antiviral solution to 15 ml conical tubes to inactivate virus before discarding. 
 
RNA Extractions 
 
Materials  
• Qiagen RNeasy Mini Kit (cat. # 74104 or 74106), used for homogenized tissues only. 
• Qiagen Viral RNA Mini Kit (cat. # 52904 or 52906), used for Nasal Washes only. 
• 10% Bleach, 70% Ethanol  
• Micropipettes and aerosol barrier pipette tips 
• Sterile, nuclease free water 
• Wet ice  
• Trizol/ TriReagent 
• Chloroform  
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Assays 
1. RNA Extraction for Homogenized Tissues 
a. Add 900µl TriReagent to sterile Eppendorf tubes and transfer 100µl of each 
homogenized tissue to a tube containing TriReagent 
i. For lung samples take 50 µl from the right and left homogenates and mix 
together, then proceed to the next step.  
b. Vortex all samples very well and let sit at room temperature for 5min with 
frequent vortexing until no visible clumps of cells are left 
c. Keep the samples at 4°C if you are not going to continue to the next step 
immediately or store them in -80°C freezer 
d. If samples are frozen, thaw to room temperature 
e. In BSC, add 200µl chloroform to each tube and invert vigorously for 20sec (DO 
NOT VORTEX) 
f. Let sit at room temperature for 3min 
g. Centrifuge at 12,000 x g for 15min at 4°C 
h. Transfer 500µl of aqueous phase (clear top layer) to a clean tube 
i. The remaining steps can be performed on a benchtop cleaned with RNase Away 
Reagent; remove tubes from BSC and clean hood with disinfectant 
j. Add 1 volume (500µl) 70% ethanol to each lysate and mix well by pipetting 
k. Transfer up to 700µl of sample at a time to RNeasy Mini Spin column inside a 
2ml collection tube (supplied in kit) 
l. Centrifuge at >8000 x g for 15sec 
m. Discard flow through and repeat with remaining sample 
n. Add 350µl Buffer RW1 to spin column 
o. Centrifuge at max speed for 30sec and discard flow-through 
p. Add 10µl DNase 1 stock solution to 70µl Buffer RDD (Note: This calculation is 
per reaction. Multiply volumes for more samples.), mix by inverting tube, and 
briefly centrifuge 
q. Add 80µl DNase 1 – Buffer RDD mixture directly to spin column membrane and 
incubate at room temperature for 15mins 
r. Add 500µl Buffer RPE to spin column, centrifuge at max speed for 30sec and 
discard flow-through 
s. Repeat step r. 
t. Place spin column in a new collection tube (supplied in kit) and centrifuge at full 
speed for 1 min to dry the membrane 
u. Place spin column in a new 1.5ml collection tube with cap (supplied in kit), add 
50μl nuclease-free water directly to the spin column membrane, and centrifuge at 
max speed for 1min to elute RNA 
v. Store samples in -80°C freezer 
 
2. RNA Extraction for Liquid Samples (Nasal Washes)  
a. Add 900µl TriReagent to sterile Eppendorf tubes and transfer 100µl of each nasal 
wash to a tube containing TriReagent 
b. Vortex all samples very well and let sit at room temperature for 5min with 
frequent vortexing until no visible clumps of cells are left 
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c. Keep the samples at 4°C if you are not going to continue to the next step 
immediately or store them in -80°C freezer 
d. If samples are frozen, thaw to room temperature 
e. In BSC, add 200µl chloroform to each tube and invert vigorously for 20sec (DO 
NOT VORTEX) 
f. Let sit at room temperature for 3min 
g. Centrifuge at 12,000 x g for 15min at 4°C 
h. Transfer 500µl of aqueous phase (clear top layer) to a clean tube 
i. The remaining steps can be performed on a benchtop cleaned with RNase Away 
Reagent; remove tubes from BSC and clean hood with disinfectant 
j. Resuspend the lyophilized 310µg of carrier RNA in 310µL Buffer AVE. Aliquot 
and store at -20°C. Avoid freeze thawing more than three times 
k. Prepare a Buffer AVL/AVE- carrier RNA solution 
i. Calculate the volume of Buffer AVL with the following equation, 
n(0.56mL) =y mL 
1. n= number of samples 
2. y= volume of Buffer AVL 
ii. Calculate the volume of Buffer AVE-carrier RNA with the following 
equation, y mL * 10µL/ mL =z µL 
1. y= volume of Buffer AVL 
2. z= volume of Buffer AVE-carrier RNA 
iii. Gently mix the two reagents by gently inverting 10 times, DO NOT 
VORTEX 
l. Into clean Eppendorf tubes pipette 560 µL of Buffer AVL/AVE- carrier RNA 
m. Add 140 µL of the aqueous phase aliquoted in step h to the Buffer AVL/AVE-
carrier RNA and mix by vortexing for 15 seconds 
n. Incubate at room temperature for 10 minutes.  
o. Centrifuge the tubes to collect droplets 
p. Add 560 µL of 100% ethanol to the sample and mix by vortexing for 15 seconds 
q. Centrifuge the tubes to collect droplets 
r. Apply 630 µL of solution to the QIAamp Mini Column with attached 2mL 
collection tube. Centrifuge at 8,000 rpm for 1 minute. Place Mini column in a new 
2mL collection tube and dispose old collection tube.  
s. Add remainder of solution to the QIAamp Mini Column. Centrifuge at 8,000 rpm 
for 1 minute. Place Mini column in a new 2mL collection tube and dispose old 
collection tube. 
t. Add 500 µL of Buffer AW1.Centrifuge at 8,000 rpm for 1 minute. Place Mini 
column in a new 2mL collection tube and dispose old collection tube. 
u. Add 500 µL of Buffer AW2.Centrifuge at 8,000 rpm for 1 minute. Place Mini 
column in a new 2mL collection tube and dispose old collection tube. 
v. Centrifuge QIAamp Mini Column at full speed for 1 minute. Place Mini Column 
in a 1.5mL Eppendorf tube  
w. Add 60 µL of room temperature Buffer AVE to the column and incubate for 1 
minute. Centrifuge at 8,000 rpm for 1 minute. Dispose of Mini column and store 
RNA at -80°C 
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Viral Titer Quantification by PCR  
 
Material/Reagents: 
• SuperscriptR III PlatinumR One-Step qRT-PCR Kit with ROX (Invitrogen, Carlsbad, 
CA, cat. #11745-100) 
• MicroAmpR Optical 96-Well Reaction Plate (Applied Biosystems™, Life Technologies, 
Thermo Scientific, cat. #4306737)  
• MicroAmp™ Optical Adhesive Film (Applied Biosystems™, Thermo Scientific, cat. 
#4311971) 
• QuantstudioTM 6 Flex Real-Time PCR System (ThermoFisher Scientific) 
• RNase/DNase-free microcentrifuge tubes 
• Nuclease-free water 
• Swine Influenza A (H1N1) real-time RT-PCR Assay (BEI Resources, NR-15577) 
• Template RNA extracted with Qiagen Viral RNA Mini Kit (cat. # 52904 or 52906) 
 
Set Up 
1. Nucleic acids extracted from Swine Influenza A (H1N1) Positive Control (NR- 15590), 
and Novel H1N1 2009 (Swine) Influenza A (NR-15627) should be diluted 1:10 prior to 
use as template in the assay 
2. Working stock aliquots of the primers and probes should be made at concentrations of 
40μM (primers) and 10μM (probes) by adding 500μl nuclease free water to each 
 
Table 4. PCR Primers and Probes for Influenza Viral Titers. 
Primers and Probes Cat # Sequence 
*Influenza A Probe NR-15578 TGC AGT CCT CGC TCA CTG GGC ACG 
Influenza A Forward NR-15579 GAC CRA TCC TGT CAC CTC TGA C 
Influenza A Reverse NR-15580 AGG GCA TTY TGG ACA AAK CGT CTA 
Swine H1 Probe NR-15584 CA GAA TAT ACA “T”CC RGT CAC AAT TGG ARA A 
Swine H1 Forward NR-15585 GTG CTA TAA ACA CCA GCC TYC CA 
Swine H1 Reverse NR-15586 CGG GAT ATT CCT TAA TCC TGT RGC 
 
*At the 5’end, TaqMan® probes are marked with the reporter molecule 6-carboxyfluorescein (FAM) and at 
the 3’end with the quencher, Blackhole Quencher 1 (BHQ1) (Biosearch Technologies, Inc., Novato, CA) 
[41]. 
**Taqman® probes are labeled at the 5'-end with the reporter molecule 6-carboxyfluorescein (FAM) and 
quenched internally at a modified “T” residue with BHQ1, with a modified 3’- end to prevent probe 
extension by Taq polymerase 
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Protocol: 
1. Thaw RNA samples and PCR reagents on ice, keep on ice throughout procedure 
2. Label one microcentrifuge tube for the master mix 
3. All samples, standards and controls should be run in duplicate 
4. Prepare master mix according to table below: 
 
Table 5. Viral Titer PCR Master Mix. 
Reagent 
Volume of Reagents 
(multiplied by number of 
reactions) 
Forward Primer N* 0.5µL 
Reverse Primer  N* 0.5µL 
*Probe N* 0.5µL 
Superscript Taq Mix N* 0.5µL 
2x PCR Master Mix  N* 12.5µL 
Nuclease Free Water N* 5.5µL 
 
* 6-carboxyfluorescein (6-FAM) probe must be protected from light 
 
5. After adding water last, mix master mix by pipetting (DO NOT VORTEX) 
6. Add 20μl master mix to all needed wells of a 96-well plate 
7. Add 5μl of each unknown sample, standard or control to each well, mix well and then 
centrifuge the plate  
a. Controls: 
i. No Template Control (NTC) containing all reagents except RNA template  
sample, use nuclease free water instead 
ii. Positive Controls containing master mix and known positive virus 
samples:  
1. Swine Influenza A (H1N1) Positive Control (NR-15590) 
2. Novel H1N1 2009 (Swine) Influenza A Positive Control (NR-
15627) should be included in each run for all primer and probe sets 
8. Wearing gloves, smooth a clear adhesive cover over the 96-well PCR plate 
9. Take plate to PCR machine on ice 
10. Make sure the QuantstudioTM 6 qPCR machine is on by checking to see if there is a green 
light on the front. If there is not or there is a red light flip the switch on the back left side 
of the machine 
11. Log onto the computer and click on the program “QuantStudio Real-Time PCR 
Software” located on the desktop  
12. Click on “New Experiment” and select the following choices on the experimental 
properties tab 
o QuantStudio 6 
o 96 Well plate, 0.2mL  
o Standard Curve 
o TaqMan® Reagents 
o Standard 
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13. Click the “Define” tab on the left and make sure in the “Targets” section the Reporter is 
listed as FAM and the Quencher as NFQ-MGB 
14. Under the “Samples” Section list samples as desired, but it is not necessary.  
15. Check that the “Passive Reference” drop down menu is selected as ROX.  
16. Click the “Assign” tab on the left and assign the Targets and Samples according to how 
the plate was set up.  
17. Click on the “Run Method” tab on the left and chose the following: 
o Reverse Transcription: 50°C for 30 minutes 
o Taq Inhibitor Activation: 95°C for 2 minutes 
o PCR Amplification (40 cycles) 
 Denature: 95°C for 15 seconds 
 Anneal: 55°C for 30 seconds 
18. Making the Standard Curve 
o Need the following  
 Virus stock with a known high titer 
• A/California/07/2009 pandemic H1N1, egg grown 2.3*108 
TCID50/mL 
 Nuclease free water 
 Eppendorf tubes 
 Need all reagents/materials from RNA isolation from liquid samples and 
PCR protocols above 
o Protocol: 
  Add 100μl virus stock sample to 900μl TriReagent in six replicates (want 
a lot of sample so can make a lot of dilutions and aliquot) 
 Perform RNA extraction procedure for liquid samples and elute RNA in 
50μl nuclease-free water 
 Combine all six replicates together (40μl x 6 ≈ 240μl) 
 Make 10-fold dilutions with nuclease-free water starting with 1:10 (10-1) 
and going down to 10-8 
 Run dilution PCR in duplicate against the remaining standard stock 
• Make sure to include a NTC 
• After PCR is complete, check the new standard against the old 
standard for accuracy 
• Calculate new standard quantities based off the original known 
virus titer (TCID50/ml) 
 
Detection of Ferret Cytokines by Two Step RT-qPCR 
 
Materials and Reagents 
• RNA Template extracted with Qiagen RNeasy Mini Kit (cat. # 74104 or 74106) 
• MicroAmpR Optical 96-Well Reaction Plate (Applied Biosystems™, Life Technologies, 
Thermo Scientific, cat. #4306737)  
• MicroAmp™ Optical Adhesive Film (Applied Biosystems™, Thermo Scientific, cat. 
#4311971) 
• QuantstudioTM 6 Flex Real-Time PCR System (ThermoFisher Scientific) 
• RNase/DNase-free microcentrifuge tubes 
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• Nuclease-free water 
• FisherbrandTM 0.2mL flat cap PCR tubes (ThermoFisher Scientific) 
• Maxima First Strand cDNA Synthesis Kit for RT-qPCR (cat# K1641) 
• Maxima SYBR Green/ROX qPCR Master Mix (2X) (cat# K0221) 
 
Protocol  
1. cDNA Synthesis  
a. Label one microcentrifuge tube for the master mix 
b. All samples, standards and controls should be run in duplicate 
c. Prepare master mix according to table below: 
 
Table 6. Reverse Transcription PCR Master Mix. 
Reagent 
Volume of Reagents 
(multiplied by number of 
reactions) 
5X Reaction Mix N* 4µL 
Maxima Enzyme Mix N* 2µL 
Template RNA 1 pg to 5µg 
Nuclease Free Water up to 20µL 
Total Volume  N* 20.0µL 
 
d. Add 15μl master mix to N+2 flat cap 0.2mL qPCR tubes.  
e. Add 5μl of each unknown sample, standard or control to each well, mix well and 
then centrifuge the plate  
i. Controls: 
1. Reverse Transcriptase Minus (RT-): includes all reagents except 
Maxima Enzyme Mix, replace this volume with nuclease free 
water 
2. No Template Control (NTC): includes all reagents except template 
RNA, replace this volume with nuclease free water 
f. Wearing gloves, smooth a clear adhesive cover over the 96-well PCR plate 
g. Take plate to PCR machine on ice to Thermocycler and set the following protocol  
i. Incubate for 10 minutes at 25°C followed by 15 minutes at 50°C, 
terminate the reaction by heating to 85°C for 5 minutes. Set an indefinite 
4°C hold to follow.  
h. Remove tubes and either start qPCR or freeze samples at -80°C 
2. qPCR 
a. Working stock aliquots of the primers should be made at concentrations of 5μM  
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Table 7. Cytokine PCR Primers 
*Primers  Sequence  
GAPDH Forward AAC ATC ATC CCT GCT TCC ACT GGT 
GAPDH Reverse TGT TGA CGC AGG AGA CAA CCT 
IFN γ Forward CCA TCA AGG AAG ACA TGC TTG TCA GG 
IFN γ Reverse CTG GAC CTG CAG ATC ATT CAC AGG AA 
TNF α Forward TGG AGC TGA CAG ACA ACC AGC TAA 
TNF α Reverse TGA TGG TGT GGG TAA GGA GCA CAT 
 
*All primers designed by Integrated DNA Technologies  
 
b. Label one microcentrifuge tube for the master mix 
c. All samples, standards and controls should be run in duplicate 
d. Prepare master mix according to table below: 
 
Table 8. Cytokine qPCR Master Mix. 
Reagent Volume of Reagent 
(multiplied by number of 
reactions) 
Maxima SYBR Green/ROX qPCR 
Master Mix 
N* 12.5µL 
Forward Primer 0.4 µM 
Reverse Primer 0.4 µM 
Template DNA < 500 ng 
Nuclease Free Water to 25µL 
Total Volume  N* 20µL 
 
e. After adding water last, mix master mix by pipetting (DO NOT VORTEX) 
f. Add  master mix to all needed wells of a 96-well plate 
g. Add unknown sample, standard or control to each well, mix well and then 
centrifuge the plate  
i. Controls: 
1. No cDNA Control (NcDC): includes all reagents except template 
DNA, replace this volume with nuclease free water 
h. Wearing gloves, smooth a clear adhesive cover over the 96-well PCR plate 
i. Take plate to PCR machine on ice 
j. Make sure the QuantstudioTM 6 qPCR machine is on by checking to see if there is 
a green light on the front. If there is not or there is a red light flip the switch on 
the back left side of the machine 
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k. Log onto the computer and click on the program “QuantStudio Real-Time PCR 
Software” located on the desktop  
l. Click on “New Experiment” and select the following choices on the experimental 
properties tab 
i. QuantStudio 6 
ii. 96 Well plate, 0.2mL  
iii. Δ ΔCT 
iv. SYBR Green 
v. Standard 
m. Click the “Define” tab on the left and make sure in the “Targets” section the 
Reporter is listed as SYBR and the Quencher as none 
n. Under the “Samples” Section list samples as desired, but it is not necessary.  
o. Check that the “Passive Reference” drop down menu is selected as ROX.  
p. Click the “Assign” tab on the left and assign the Targets and Samples according 
to how the plate was set up.  
q. Click on the “Run Method” tab on the left and chose the following: 
i. UDG pre-treatment: 50°C for 2 minutes 
ii. Initial denaturation: 95°C 10 minutes 
iii. PCR Amplification (40 cycles) 
1. Denaturation: 95°C for 15 seconds 
2. Anneal: 60°C for 30 seconds 
3. Extension: 72°C for 30 seconds 
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APPENDIX B: SUPPLEMENTAL RESULTS 
B.1 PROPHYLACTIC STUDY  
Table 9. Inhaled Dose of Influenza for Group 1. 
Group Number (Date) Ferret ID Treatment A13r33 Inhaled Dose (TCID50) 
1 (4/18) FT-001 5mg/ kg Intranasal 1.74E+06 
1 (4/18) FT-004 5mg/ kg Intratracheal 1.74E+06 
1 (4/18) FT-008 Control 1.39E+06 
Run 1 Average   1.62E+06 
2 (4/18) FT-003 5mg/ kg Intranasal 5.41E+06 
2 (4/18) FT-005 5mg/ kg Intratracheal 5.13E+06 
2 (4/18) FT-009 Control 5.04E+06 
Run 2 Average   5.19E+06 
3 (4/18) FT-002 5mg/ kg Intranasal 5.13E+06 
3 (4/18) FT-006 5mg/ kg Intratracheal 4.48E+06 
3 (4/18) FT-007 Control 5.04E+06 
Run 3 Average   4.88E+06 
 
Table 10. Inhaled Dose of Influenza for Group 2. 
Group Number (Date) Ferret ID Treatment A13r33 Inhaled Dose (TCID50) 
1 (5/5) FT-012 5mg/ kg Intranasal 5.04E+04 
1 (5/5) FT-015 5mg/ kg Intratracheal 5.32E+04 
1 (5/5) FT-016 Control 4.86E+04 
Run 1 Average   5.07E+04 
2 (5/5) FT-010 5mg/ kg Intranasal 3.56E+05 
2 (5/5) FT-017 5mg/ kg Intratracheal 3.44E+05 
2 (5/5) FT-014 Control 3.37E+05 
Run 2 Average   3.46E+05 
3 (5/5) FT-011 5mg/ kg Intranasal 8.20E+05 
3 (5/5) FT-013 5mg/ kg Intratracheal 7.54E+05 
3 (5/5) FT-018 Control 8.72E+05 
Run 3 Average   8.15E+05 
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Table 11. Temperature (°C) of Ferrets in Group 1. 
Ferret ID Temperature( °C) 
  
Pre-
infection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 (Necro) 
FT-001 37.8 39.1 37.3 38.4 38.6 38.7 38.3 38.5 
FT-002 38.4 38.7 39.2 38.4 38.3 37.7 38.2 38.8 
FT-003 38.6 38.1 39.5 39.2 39.5 39.1 39 38.8 
FT-004 35.4 36.1 36.3 36.5 36.4 36.2 36.2 36.3 
FT-005 37.8 38.9 38.7 38.6 38.6 38.5 38.1 38.2 
FT-006 37.6 35.1 39.4 38.1 38 38.1 38.6 38.5 
FT-007 n/a 37 39.6 38.4 38.3 38.5 38 39 
FT-008 37.9 39 39.3 38.5 38.1 38.2 39.1 39.1 
FT-009 n/a 36.5 38.7 38.4 38.9 38.4 38.7 38.7 
 
Table 12. Temperature (°C) of Ferrets in Group 2. 
 
Ferret ID Temperature( °C) 
  
Pre-
infection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 (Necro) 
FT-010 37.9 38.1 39.1 38.5 38.5 38.1 38.2 37.9 
FT-011 37.4 38.6 38.3 38.7 38.6 36.8 37.4 37.4 
FT-012 37.8 39.7 39.4 39.1 39.2 39 38.3 37.8 
FT-013 40.3 40.5 41.1 41.4 41.1 40.8 40.7 39.9 
FT-017 38.3 38.2 39.5 39 38.8 38.6 38.9 38.5 
FT-015 38.2 38.9 38.9 39.4 38.8 38.7 38.4 38.7 
FT-016 37.7 39 40 39.1 39.1 39.3 38.4 39.2 
FT-018 37.8 38.8 39.7 38.9 38.3 38.2 38.2 39.9 
FT-014 38.4 39.1 39.1  39.2 39.1 39.5 38.1 38.4 
 
Table 13. Weights (kg) of Ferrets in Group 2. 
 
Ferret ID Weights (kg) 
  
Pre-
infection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 (Necro) 
FT-001 0.46 0.46 0.39 0.39 0.41 0.39 0.36 0.38 
FT-002 0.42 0.4 0.33 0.34 0.35 0.32 0.3 0.35 
FT-003 0.45 0.44 0.36 0.4 0.41 0.4 0.39 0.4 
FT-004 0.46 0.44 0.41 0.41 0.41 0.42 0.41 0.43 
FT-005 0.42 0.42 0.35 0.34 0.34 0.34 0.35 0.36 
FT-006 0.35 0.37 0.33 0.34 0.35 0.34 0.31 0.31 
FT-007 0.41 0.41 0.34 0.35 0.33 0.3 0.29 0.32 
FT-008 0.34 0.36 0.3 0.32 0.31 0.31 0.31 0.32 
FT-009 0.41 0.42 0.37 0.38 0.39 0.37 0.37 0.38 
 99 
Table 14. Weights (kg) of Ferrets in Group 2. 
Ferret ID Weights (kg) 
  
Pre-
infection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 (Necro) 
FT-010 0.43 0.37 0.39 0.34 0.37 0.38 0.43 0.47 
FT-011 0.47 0.43 0.4 0.38 0.36 0.34 0.36 0.37 
FT-012 0.41 0.38 0.37 0.34 0.37 0.38 0.39 0.41 
FT-013 0.42 0.42 0.41 0.38 0.4 0.4 0.39 0.4 
FT-017 0.41 0.4 0.37 0.38 0.38 0.38 0.37 0.38 
FT-015 0.44 0.45 0.41 0.41 0.43 0.43 0.43 0.44 
FT-016 0.39 0.38 0.36 0.36 0.37 0.36 0.36 0.34 
FT-018 0.51 0.5 0.48 0.48 0.49 0.48 0.53 0.48 
FT-014 0.4 0.4 0.38 0.39 0.4 0.39 0.39 0.4 
 
Table 15. Clinical Scores of Ferrets in Group 1. 
Ferret ID Clinical Scores 
  
Pre-
infection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 (Necro) 
FT-001 0 7 19 25 18 18 13 11 
FT-002 0 5 22 24 26 26 13 11 
FT-003 0 7 25 25 25 24 15 13 
FT-004 0 9 11 12 15 11 11 9 
FT-005 0 7 17 24 26 24 12 9 
FT-006 0 7 15 22 19 19 18 18 
FT-007 0 9 34 29 29 29 27 20 
FT-008 0 12 29 27 27 24 24 20 
FT-009 5 10 18 27 25 20 19 15 
 
Table 16. Clinical Scores of Ferrets in Group 2. 
 Ferret ID Clinical Scores 
 
Pre-
infection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 (Necro) 
FT-010 0 0 5 7 9 13 11 4 
FT-011 0 9 11 11 11 20 18 2 
FT-012 0 0 7 7 9 13 15 4 
FT-013 0 2 4 19 18 14 11 9 
FT-017 0 2 11 19 19 21 19 17 
FT-015 0 2 7 19 19 19 16 14 
FT-016 0 2 14 24 26 24 16 23 
FT-018 0 2 7 17 19 16 21 16 
FT-014 0 4 11 21 14 14 11 13 
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B.2 PILOT STUDY 
Table 17. Inhaled Dose of Influenza. 
Ferret ID Infection Route Titer Virus Received (TCID50) 
FT-003 Aerosol  104.45 
FT-004 Aerosol 104.45 
FT-002 Intranasal 104.2 
FT-007 Intranasal  104.2 
FT-005 Uninfected Not Applicable  
FT-006 Uninfected  Not Applicable 
 
Table 18. Temperature (°C) of Ferrets. 
 
Ferret ID     
 Pre-infection Day 1 Day 2 Day 3 (Necro) 
FT-003 38.8 38.8 38.7 38.8 
FT-004 39 39 39.8 39.9 
FT-002 38.3 38.3 39.2 39. 
FT-007 38.6 38.6 39.2 39 
FT-005 Not collected Not collected Not collected Not collected 
FT-006 Not collected Not collected Not collected Not collected 
 
Table 19. Weight (kg) of Ferrets. 
Ferret ID Weight (kg) 
 Pre-infection Day 1 Day 2 Day 3 (Necro) 
FT-003 0.93 0.93 0.93 0.9 
FT-004 0.88 0.88 0.88 0.87 
FT-002 1.04 1.04 1.04 1.06 
FT-007 0.94 0.94 0.93 0.93 
FT-005 1.05 1.06 1.06 1.07 
FT-006 1.05 1.06 1.06 1.07 
 
Table 20. Clinical Scores of Ferrets. 
Ferret ID     
 Pre-infection Day 1 Day 2 Day 3 (Necro) 
FT-003 0 2 8 18 
FT-004 0 2 8 21 
FT-002 0 0 4 4 
FT-007 0 2 4 4 
FT-005 0 0 0 0 
FT-006 0 0 0 0 
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Table 21. TCID50 Raw Data for Nasal Washes, Right, and Left Lung. 
Table 22. TCID50 Raw Data for Trachea, Soft Palate, and Nasal Turbinates. 
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APPENDIX C: FORMULAS 
Table 23. Calculation to Determine TCID50 
  
Number 
Infected 
Eggs/Wells 
(+ve) 
Number 
Uninfected 
Eggs/Wells         
(-ve) 
Accumulated numbers Percentage infected 
Infected     
(A) 
Add from 
BOTTOM  up 
Uninfected 
(B) 
Add from   
TOP down 
Total 
(A+B) A/(A+B) × 100 
10-6 5 0 11 0 11 11/11 = 100% 
 *10-7 4 1 6 1 7 6/7 = 86% 
10-8 1 4 2 5 7 2/7 = 29% 
10-9 1 4 1 9 10 1/10 = 10% 
10-10 0 5 0 14 14 0/14 = 0% 
• Determine the dilution of inoculum producing 50 percent infection of eggs or cells 
 
• If necessary, use the Reed Muench formula to calculate the index: 
 
• Apply the index calculated using this formula to the dilution that produced the infection rate immediately 
above 50 percent = 10-7.6 
 
• (Mark dilution with *) 
 
• This dilution of the virus suspension contained one EID50 or TCID50 unit of virus in 0.1 mL (or whatever 
volume virus was added to egg/first well 96- well plate (ex. 20ul/96 well plate) 
 
• 1 mL of the virus suspension will contain ten times the reciprocal of the calculated dilution (if added 100ul) 
or 50x the reciprocal calculated dilution (if added 20ul). 
 
• Therefore Infectivity Titer of virus suspension in EID50/mL = 10 × 107.6 = 108.6 EID50/mL  OR TCID50/mL 
= 50 x 107.6 =  
 
 
 103 
BIBLIOGRAPHY 
1. Lina B. 2008. History of Influenza Pandemdics p199-211, Raoult D and Drancourt M 
(Eds) Paleomicrobiology: Past human infection. Springer, Marseilles, France. 
2. Taubenberger J, Morens D. 2006. 1918 Influenza: the Mother of All Pandemics. Emerg 
Infect Dis 12:15-22. 
3. Radigan K, Misharin A, Chi M, Budinger G. 2015. Modeling human influenza 
infection in the laboratory. Infection and Drug Resistance 8:311-320. 
4. Rogers G, Paulon J, Daniels R, Skehel J, Wilson I, Wiley D. 1983. Single amino acid 
substitutions in influenza haemagglutinin change receptor binding specificity. Nature 
304:76-78. 
5. Weis W, Brown J, Cusack S, Paulson J, Skehel K, Wiley D. 1988. Structure of the 
influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333:426-
431. 
6. Shtyrya Y, Mochalova L, Bovin N. 2009. Influenza Virus Neuraminidase: Structure and 
Function. Acta Naturae 1:26-32. 
7. Varki A. 2009 Sialic acids in human health and disease. Trends Mol Med 14:351-360. 
8. Luo M. 2012. Influenza virus entry. Adv Exp Med Biol 726:201-221. 
9. Samji T. 2009. Influenza A: Understanding the Viral Life Cycle. Yale J Biol Med 
82:153-159. 
10. Li M, Rao P, Krug R. 2001. The active sites of the influenza cap-dependent 
endonuclease are on different polymerase subunits. EMBO J 20:2078-2086. 
11. Rossman J, Lamb R. 2011. Influenza Virus Assembly and Budding. Virology 411:229-
236. 
12. Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, Wortley P, Weintraub 
E, Bridges C. 2007. The annual impact of seasonal influenza in the US: measuring 
disease burden and costs. Vaccine 25:5086-5096. 
13. Thompson W, Weintraub E, Dhankhar P, Cheng P, Brammer L, Meltzer M, Bresee 
J, Shay D. 2008. Estimates of US influenza-associated deaths made using four different 
methods. . Influenza Other Respir Viruses 3:37-49. 
14. Dowdle WR. 1999. Influenza A virus recycling revisted. Bull World Health Organ 
77:820–828. 
15. Kilbourne ED. 2006. Pandemics of the 20th Century. Emerg Infect Dis 12:9-14. 
16. Louria D.D., Blumenfeld H.L., Ellis J.T., Kilbourne E.D., D.E. R. 1959. Studies on 
influenza in the pandemic of 1957–58. II. Pulmonary complications of influenza. . J Clin 
Invest 38:213–265. 
 104 
17. Viboud C., Grais R.F., Lafont B.A., Miller M.A., L. S. 2005. Multinational impact of 
the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect 
Dis 192:233-248. 
18. Rozo M, Groncall GK. 2015. The Reemergent 1977 H1N1 Strain and the Gain-of-
Function Debate. American Society for Microbio 6. 
19. Saunders-Hastings PR, Krewski D. 2016. Reviewing the History of Pandemic 
Influenza: Understanding Patterns of Emergence and Transmission. Pathogens 5. 
20. Gibbs AJ, Armstrong JS, Downie JC. 2009. From where did the 2009 'swine-origin' 
influenza A virus (H1N1) emerge? Virology Journal 6. 
21. Cox NJ, Subbarao K. 2000. Global Epidemiology of Influenza: Past and Present. Annu 
Rev Med 51:407-421. 
22. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. 2005. Influenza virus-
like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce 
protective immune responses in BALB/c mice. Vaccine 23:5751–5759. 
23. Brauer R, Chen P. 2015. Influenza Virus Propagation in Embryonated Chicken Eggs. 
Journal of Visualized Experiments 97. 
24. Flannery B, Clippard J, Zimmerman R, Norwalk M, Jackson M, Jackson L, Monto 
A, Petrie J, McLean H, Belongia E, Gaglani M, Berman L, Foust A, Sessions W, 
Thaker S, Spencer S, Fry A. 2015. Early Estimates of Seasonal Influenza Vaccine 
Effectiveness MMWR Morb Mortal Wkly Rep 64:10-15. 
25. Gubareva L, Kaiser L, Hayden F. 2000. Influenza virus neuraminidase inhibitors. The 
Lancet 355:827-835. 
26. Borio L, Toner E, Bartlett J. 2005. Overview of Oseltamivir Phosphate (Tamiflu®) and 
Key Points, abstr Joint Meeting of the National Vaccine Advisory Committee and the 
Advisory Committee on Immunization Practices, Johns Hopkins Bloomberg School of 
Public Health  
27. Winquist A, Fukudu K, Bridges C, Cox N. 1999. Neuraminidase Inhibitors for 
Treatment of Influenza A and B Infections.  Centers for Disease COntrol  
28. Schnell J, Chou J. 2008. Structure and mechanism of the M2 proton channel of 
influenza A virus. Nature 451:591-595. 
29. Wang C, Takeuchi K, Pinto L, Lamb R. 1993. Ion channel activity of influenza A virus 
M2 protein: characterization of the amantadine block. Journal of Virology 67:5585 - 
5594. 
30. Pielak R, Chou J. 2012. Influenza M2 proton channels. Biochim Biophys Acta 
1808:522-529. 
31. Pielak R, Schnell J, Chou J. 2009. Mechanism of drug inhibition and drug resistance of 
influenza A M2 channel. Proc Natl Acad Sci 106:7379 –7384. 
32. Ruigrok R, Hirst E, Hay A. 1991. The specific inhibition of influenza A virus 
maturation by amantadine: an electron microscopic examination. J Gen Virol 72:191-
194. 
33. Muthuri S, Venkatesan S, Myles P, Leonardi-Bee J, Al Khuwaitir T, Al Mamun A, 
Anovadiya A, Azziz-Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, 
Bonmarin I, Booy R, Borja-Aburto V, Burgmann H, Cao B, Carratala J, Denholm 
J, Dominguez S, Duarte P, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, 
Gérardin P, Giannella M, Gubbels S, Herberg J, Iglesias A, Hoger P, Hu X, Islam 
Q, Jiménez M, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, 
 105 
Kuzman I, Kwan A, Amine I, Langenegger E, Lankarani K, Leo Y, Linko R, Liu P, 
Madanat F, Mayo-Montero E, et al. 2014. Effectiveness of neuraminidase inhibitors in 
reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus 
infection: a meta-analysis of individual participant data. The Lancet Respiratory 
Medicine 2:395 - 404. 
34. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat I, Kondo H, Suzuki Y, 
Saito K, Suzuki H. 2012. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, 
zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and 
A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in 
Japan. J Infect Chemother 18:858-864. 
35. Treanor J, Hayden F, Vrooman P. 2000. Efficacy and Safety of the Oral 
Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized 
Controlled Trial. JAMA 283:1016-1024. 
36. Oxford J, Bossuyt S, Balasignam S, Mann A, Novelli P, Lambkin R. 2003. Treatment 
of epidemic and pandemic influenza with neuraminidase and M2 proton channel 
inhibitors. Clinical Microbiology and Infection 9:1-14. 
37. Jefferson T, Mark J, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ, al. e. 2014. 
Oseltamivir for influenza in adults and children: systematic review of clinical study 
reports and summary of regulatory comments. BMJ 348. 
38. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin M, Boivin G. 2009. Emergence of 
Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis. New England Journal 
of Medicine 361:2296-2297. 
39. Anonymous. 2009. Antiviral use and the risk of drug resistance: pandemic (H1N1) 2009 
briefing note 12.  World Health Organization, Geneva. 
40. Ives J, Carr J, Mendel D, Tai C, Lambkin R, Kelly L, Oxford J, Hayden F, Roberts 
N. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site 
following oseltamivir phosphate treatment leave virus severely compromised both in 
vitro and in vivo. Antiviral Res 55:307-317. 
41. Boivin G, Coulombe Z, Wat C. 2003. Quantification of the Influenza Virus Load by 
Real-Time Polymerase Chain Reaction in Nasopharyngeal Swabs of Patients Treated 
with Oseltamivir. Journal of Infectious Diseases 188:578-580. 
42. Bouvier NM, Lowen AC. 2010. Animal Models for Influenza Virus Pathogenesis and 
Transmission. Viruses 2:1530–1563. 
43. Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O. 1988. Influenza virus-susceptible 
mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol 8:4518–
4523. 
44. Matsuoka Y, Lamirande E, Subbarao K. 2009. The Mouse Model fo Influenza Current 
Protocols in Microbiology doi:10.1002/9780471729259.mc15g03s13. 
45. Belser J, Katz J, Tumpey T. 2011. The ferret as a model organism to study influenza A 
virus infection. Dis Model Mech 4:575-579. 
46. Yang Y.T., C.A. E. 1961. Hypothermia in mice due to influenza virus infection. Proc 
Soc Exp Biol Med 108:776–780. 
47. Ning ZY, Luo M, Qi WB, Yu B, Jiao PR, Liao M. 2009. Detection of expression of 
influenza virus receptors in tissues of BALB/c mice by histochemistry. Vet Res Commun 
33. 
 106 
48. Dybing JK, Schultz-Cherry S, Swayne DE, Suarez DL, Perdue ML. 2000. Distinct 
Pathogenesis of Hong Kong-Origin H5N1 Viruses in Mice Compared to That of Other 
Highly Pathogenic H5 Avian Influenza Viruses. J Virol 74:1443–1450. 
49. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, 
Kawaoka Y. 2007. Growth of H5N1 Influenza A Viruses in the Upper Respiratory 
Tracts of Mice. PLOS Pathogens 3. 
50. Lowen A, Mubareka S, Tumpey T, García-Sastre A, Palese P. 2006. The guinea pig 
as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A 
103:9988–9992. 
51. Karlsson EA, Engel GA, Feeroz MM, San S, Rompis A, Lee BPY-H, Shaw E, Oh G, 
Schillaci MA, Grant R, Heidrich J, Schultz-Cherry S, Jones-Engel L. 2012. Influenza 
Virus Infection in Nonhuman Primates. Emerging Infectious Diseases, 18:1672–1675. 
52. Kobasa D., Jones S.M., Shinya K., Kash J.C., Copps J., Ebihara H., Hatta Y., Kim 
J.H., Halfmann P., Hatta M., Feldmann F., Alimonti J.B., Fernando L., Li Y., Katze 
M.G., Feldmann H., Y.. K. 2007. Aberrant innate immune response in lethal infection of 
macaques with the 1918 influenza virus. Nature 445:319-323. 
53. Huff JL, Barry PA. 2003. B-Virus (Cercopithecine herpesvirus 1) Infection in Humans 
and Macaques: Potential for Zoonotic Disease. Emerging Infectious Diseases, 9:246-250. 
54. Koday M, Nelson J, Chevalier A, Koday M, Kalinoski H, Stewart L, Carter L, 
Nieusma T, Lee P, Ward A, Wilson I, Dagley A, Smee D, Baker D, Fuller D. 2016. A 
Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo 
Protection from Influenza Independent of a Host Immune Response. PLOS Pathogens 12. 
55. Brichacek A. 2016. Evaluation of a Novel Computationally-Desgned Antivral for 
Influenza Infection in the Ferret Model. Masters of Science University of Pittsburgh 
Pittsburgh, Pennsylvania. 
56. Gillman A., Muradrasolib S, Söderströmd H, Holmberga F, Latorre-Margalefe N, 
Tolf C, Waldenströme J, Gunnarssonf G, Olsena B, J.D. J. 2015. Oseltamivir-
Resistant Influenza A (H1N1) Virus Strain with an H274Y Mutation in Neuraminidase 
Persists without Drug Pressure in Infected Mallards. Appl Environ Microbiol 81: 2378-
2383. 
57. Corti D, et al. 2011. A Neutralizing Antibody Selected from Plasma Cells That Binds to 
Group 1 and Group 2 Influenza A Hemagglutinins. Science 
doi:10.1126/science.1205669. 
58. Brichacek A. 2016. Evaluation of a Novel Computationally-Designed Antiviral for 
Influenza Infection in the Ferret Model. Masters of Science University of Pittsburgh, 
Pittsburgh. 
59. Vogel AJ, Harris S, Marsteller N, Condon SA, Brown DM. 2014. Early Cytokine 
Dysregulation and Viral Replication Are Associated with Mortality During Lethal 
Influenza Infection. Viral Immunol 27:214–224. 
60. De Jong MD, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated 
with high viral load and hypercytokinemia. Nature Medicine, 12:1203-1207. 
61. Tran V, et al. 2013. Highly Sensitive Real-Time In Vivo Imaging of an Influenza 
Reporter Virus Reveals Dynamics of Replication and Spread. Journal of Virology 
87:13321–13329  
62. Karlsson EA, et al. 2015. Visualizing Real-time Influenza Virus Infection, Transmission 
and Protection in Ferrets. Nature Communications 6. 
 107 
63. Frise R, Bradley K, van Doremalen N, Galiano M, Elderfield RA, Stilwell P, 
Ashcroft JW, Fernadez-Alonso M, Miah S, Lackenby A, ROberts KL, Donnely CA, 
Barclay WS. 2016. Contact transmission of influenza virus between ferrets imposes a 
looser bottleneck than respiratory droplet transmission allowing propagation of antiviral 
resistance. Scientific Reports 6. 
64. Lackemeyer M, de Kok-Mercado F, Wada J, Bollinger, L, , Kindrachuk J, Wahl-
Jensen V, Kuhn J, Jahrling P. 2014. ABSL-4 Aerobiology Biosafety and Technology at 
the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses 6:137-150. 
65. Livak KJ, Schmittgen TD. 2001. Analysis of Relative Gene Expression Data Using 
RealTime Quantitative PCR and the 2-DeltaDeltaCT Method. Methods 25:402-408. 
66. Ng S, Cowling BJ, Fang VJ, Chan KH, Ip DKM, Cheng CKY, Uyeki TM, Houck 
PM, Peiris JSM, Leung GM. 2010. Effects of oseltamivir treatment on duration of 
clinical illness and viral shedding, and household transmission of influenza virus. . Clin 
Infect Dis 50:707–714. 
67. Imai M., Watanabe T., Hatta M., Das S.C., Ozawa M., Shinya K., Zhong G., Hanson 
A., Katsura H., Watanabe S., Li C., Kawakami E., Yamada S., Kiso M., Suzuki Y., 
Maher E.A., Neumann G., Y. K. 2012. Experimental adaptation of an influenza H5 HA 
confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. 
Nature 486:420-428. 
68. Smith A, et al. 2016. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, 
and Safety of Therapeutic Proteins. J Immunol Res doi:10.1155/2016/2342187. 
 
 
 
 
 
